Tissue ablation may be used to treat a variety of clinical disorders. For example, tissue ablation may be used to treat cardiac arrhythmias by at least partially destroying (e.g., at least partially or completely ablating, interrupting, inhibiting, terminating conduction of, otherwise affecting, etc.) aberrant pathways that would otherwise conduct abnormal electrical signals to the heart muscle. Several ablation techniques have been developed, including cryoablation, microwave ablation, radio frequency (RF) ablation, and high frequency ultrasound ablation. For cardiac applications, such techniques are typically performed by a clinician who introduces a catheter having an ablative tip to the endocardium via the venous vasculature, positions the ablative tip adjacent to what the clinician believes to be an appropriate region of the endocardium based on tactile feedback, mapping electrocardiogram (ECG) signals, anatomy, and/or fluoroscopic imaging, actuates flow of an irrigant to cool the surface of the selected region, and then actuates the ablative tip for a period of time and at a power believed sufficient to destroy tissue in the selected region.
Successful electrophysiology procedures require precise knowledge about the anatomic substrate. Additionally, ablation procedures may be evaluated within a short period of time after their completion. Cardiac ablation catheters typically carry only regular mapping electrodes. Cardiac ablation catheters may incorporate high-resolution mapping electrodes. Such high-resolution mapping electrodes provide more accurate and more detailed information about the anatomic substrate and about the outcome of ablation procedures. High-resolution mapping electrodes can allow the electrophysiology to evaluate precisely the morphology of electrograms, their amplitude and width and to determine changes in pacing thresholds. Morphology, amplitude and pacing threshold are accepted and reliable electrophysiology (EP) markers that provide useful information about the outcome of ablation.
According to some embodiments, a system for delivering energy to targeted cardiac tissue of a subject and for confirming successful ablation of said targeted cardiac tissue comprises a medical instrument (e.g., catheter) comprising a high-resolution (e.g., split-tip) electrode along a distal end of the catheter, an energy delivery module comprising a processor, the energy delivery module being configured to operatively couple to the catheter, wherein the energy delivery module is configured to energize the electrode to selectively ablate targeted cardiac tissue adjacent the electrode, wherein the energy delivery module is configured to couple to a pacemaker for selectively pacing cardiac tissue in order to attain capture of the heart of the subject, wherein the system is configured, via a predetermined pacing signal provided to the catheter by the pacemaker, to increase the heart rate of the subject from a baseline level to an elevated level, the predetermined pacing signal comprising a pacing level greater than a pre-ablation pacing threshold level, and wherein the processor is configured to terminate the delivery of energy to the electrode after loss of capture of the heart of the subject.
According to some embodiments, wherein the pacemaker is included in the system, the pacemaker is integral to the energy delivery module. In some embodiments, the energy delivery module is configured to deliver radiofrequency (RF) energy to the electrode, wherein the energy delivery module comprises a radiofrequency (RF) generator, wherein the high-resolution electrode comprises a distal portion and a proximal portion, the distal and proximal portions of the high-resolution electrode being operatively coupled to each other using at least one filtering element, wherein the filtering element comprises a capacitor, wherein the pacing level of predetermined pacing signal is 5 to 20 milliamps (mA), wherein the elevated level of the heart rate upon pacing the cardiac tissue at the predetermined pacing level is 100 to 200 beats per minute (bpm), and wherein the energy delivery module comprises at least one filter, the at least one filter being configured to isolate a signal relating to the localized heart rate signal measured using the high-resolution mapping electrode.
According to some embodiments, the pacemaker is included in the system, wherein the high-resolution electrode comprises a distal portion and a proximal portion, the distal and proximal portions of the high-resolution electrode being operatively coupled to each other using at least one filtering element, wherein the filtering element comprises a capacitor, wherein the pacing level of predetermined pacing signal is 5 to 20 milliamps (mA), and wherein the elevated level of the heart rate upon pacing the cardiac tissue at the predetermined pacing level is 100 to 200 beats per minute (bpm).
According to some embodiments, the pacemaker is integral to the energy delivery module. In some embodiments, the pacemaker is separate from the energy delivery module. In some arrangements, the pacemaker is included in the system. In some embodiments, the pacemaker is not included in the system. In some embodiments, the energy delivery module is configured to deliver radiofrequency (RF) energy to the electrode. In some embodiments, the high-resolution electrode comprises a distal portion and a proximal portion, the distal and proximal portions of the high-resolution electrode being operatively coupled to each other using at least one filtering element. In some embodiments, the at least one filtering element comprises a capacitor.
According to some embodiments, the catheter further comprises at least one additional mapping electrode. In some embodiments, the energy delivery module comprises a radiofrequency (RF) generator. In some embodiments, the energy delivery module comprises at least one filter, the at least one filter being configured to isolate a signal relating to the localized heart rate signal measured using the high-resolution mapping electrode. In some embodiments, the pacing level of predetermined pacing signal is 5 to 20 milliamps (mA) (e.g., 5-6, 6-7, 7-8, 8-9, 9-10, 10-11, 11-12, 12-13, 13-14, 14-15, 15-16, 16-17, 17-18, 18-19, 19-20 mA, etc.). In some embodiments, the pacing level of predetermined pacing signal is 10 to 15 milliamps (mA).
According to some embodiments, the elevated level of the heart rate upon pacing the cardiac tissue at the predetermined pacing level is 100 to 200 beats per minute (bpm) (e.g., e.g., 100-105, 105-110, 110-115, 115-120, 120-125, 125-130, 130-135, 135-140, 140-145, 145-150, 150-155, 155-160, 160-165, 165-170, 170-175, 175-180, 180-185, 185-190, 190-195, 195-200 bpm, etc.). In some embodiments, the elevated level of the heart rate upon pacing the cardiac tissue at the predetermined pacing level is 120 to 150 beats per minute (bpm). In some embodiments, the pre-ablation pacing threshold level is 0.1 to 3 milliamps (mA) (e.g., 0.1-0.2, 0.2-0.3, 0.3-0.4, 0.4-0.5, 0.5-0.6, 0.6-0.7, 0.7-0.8, 0.8-0.9, 0.9-1.0, 1.0-1.1, 1.1-1.2, 1.2-1.3, 1.3-1.4, 1.4-1.5, 1.5-1.6. 1.6-1.7, 1.7-1.8, 1.8-1.9, 1.9-2, 2-2.5, 2.5-3 mA, etc.). In some embodiments, the pre-ablation pacing threshold level is 0.5 to 2 milliamps (mA).
According to some embodiments, the processor is configured to terminate the delivery of energy to the electrode as soon as the heart rate drops below the elevated level or after loss of capture of the heart of the subject. In some embodiments, the processor is configured to terminate the delivery of energy to the electrode following a pre-determined time period after the heart rate drops below the elevated level or after loss of capture of the heart of the subject. In some embodiments, the predetermined time period comprises 0.5 to 10 seconds (e.g., 0.5-1, 1-2, 2-3, 3-4, 4-5, 5-6, 6-7, 7-8, 8-9, 9-10 seconds, values between the foregoing ranges, etc.). In some embodiments, the predetermined time period comprises 1 to 5 seconds.
According to some embodiments, delivery of energy is terminated by an operator with or without a time period after the heart rate drops below the elevated level or after loss of capture of the heart of the subject. In some embodiments, the system further includes at least one output configured to receive data related to the subject's heart rate. In some embodiments, the at least one output comprises a display (e.g., a monitor or other display, etc.). In some embodiments, the at least one output is integrated within the system. In other configurations, the at least one output is separate from the system. In some embodiments, data related to the subject's heart rate are provided via and processed by an EP recording system.
According to some embodiments, a method of ablating and confirming successful ablation of targeted cardiac tissue of a subject using a high-resolution mapping electrode includes pacing said cardiac tissue at a predetermined pacing level to capture the heart of the subject, thereby increasing a heart rate of the subject from a baseline level to an elevated level, delivering ablative energy to the ablation electrode while pacing, the ablation electrode comprising a high-resolution electrode (e.g., a split-tip electrode), wherein the predetermined pacing level exceeds a pre-ablation threshold level, wherein capture of the heart of the subject occurs once the pacing level exceeds the pre-ablation level, and wherein the heart rate of the subject drops below the elevated level when capture of the heart of the subject is lost. The method additionally includes terminating the delivery of ablative energy to the ablation electrode after capture of the heart of the subject is lost.
According to some embodiments, a method of confirming successful ablation of targeted cardiac tissue of a subject using a high-resolution mapping electrode includes pacing said cardiac tissue at a predetermined pacing level to increase a heart rate of the subject from a baseline level to an elevated level, the predetermined pacing level being greater than a pre-ablation pacing threshold level and less than a post-ablation pacing threshold level, delivering ablative energy to the ablation electrode while pacing, the ablation electrode comprising a high-resolution electrode, wherein the heart rate of the subject is at the elevated level once the pre-ablation threshold level is exceeded, but before the post-ablation pacing threshold level is reached, and wherein the heart rate of the subject drops below the elevated level once the ablation electrode has successfully ablated adjacent tissue of the subject, the heart rate has dropped below the elevated level as the post-ablation pacing threshold level is greater than the predetermined pacing level. The method additionally comprises terminating the delivery of ablative energy to the ablation electrode after the heart rate of the subject drops below the elevated level.
According to some embodiments, pacing cardiac tissue is performed via an energy delivery module that is configured to deliver ablative energy to the ablation electrode. In some embodiments, the energy delivery module comprises a radiofrequency (RF) generator. In some embodiments, pacing the cardiac tissue comprises operatively coupling a pacemaker to an energy delivery module that is configured to deliver ablative energy to the ablation electrode. In some embodiments, the pacemaker is integral with the energy delivery module (e.g., RF generator). In some embodiments, the pacemaker is separate from the energy delivery module.
According to some embodiments, the predetermined pacing level is 5 to 20 milliamps (mA) (e.g., 5-6, 6-7, 7-8, 8-9, 9-10, 10-11, 11-12, 12-13, 13-14, 14-15, 15-16, 16-17, 17-18, 18-19, 19-20 mA, etc.). In some embodiments, the pacing threshold is 10 to 15 milliamps (mA). In some embodiments, the elevated level of the heart rate upon pacing the cardiac tissue at the predetermined pacing level is 100 to 200 beats per minute (bpm) (e.g., e.g., 100-105, 105-110, 110-115, 115-120, 120-125, 125-130, 130-135, 135-140, 140-145, 145-150, 150-155, 155-160, 160-165, 165-170, 170-175, 175-180, 180-185, 185-190, 190-195, 195-200 bpm, etc.). In some embodiments, the elevated level of the heart rate upon pacing the cardiac tissue at the predetermined pacing level is 120 to 150 beats per minute (bpm). In some embodiments, the pre-ablation pacing threshold level is 0.1 to 3 milliamps (mA) (e.g., 0.1-0.2, 0.2-0.3, 0.3-0.4, 0.4-0.5, 0.5-0.6, 0.6-0.7, 0.7-0.8, 0.8-0.9, 0.9-1.0, 1.0-1.1, 1.1-1.2, 1.2-1.3, 1.3-1.4, 1.4-1.5, 1.5-1.6. 1.6-1.7, 1.7-1.8, 1.8-1.9, 1.9-2, 2-2.5, 2.5-3 mA, etc.). In some embodiments, the pre-ablation pacing threshold level is 0.5 to 2 milliamps (mA). In some embodiments, the post-ablation pacing threshold level is greater than 10 milliamps (mA). In some embodiments, the post-ablation pacing threshold level is greater than 20 milliamps (mA).
According to some embodiments, terminating the delivery of ablative energy to the ablation electrode occurs immediately after the heart rate of the subject drops below the elevated level or after capture of the heart of the subject is lost. In some embodiments, terminating the delivery of ablative energy to the ablation electrode occurs following a predetermined time period after the heart rate of the subject drops below the elevated level or after capture of the heart of the subject is lost. In some embodiments, the predetermined time period comprises 0.5 to 10 seconds (e.g., 0.5-1, 1-2, 2-3, 3-4, 4-5, 5-6, 6-7, 7-8, 8-9, 9-10 seconds, values between the foregoing ranges, etc.). In some embodiments, the predetermined time period comprises 1 to 5 seconds. In some embodiments, delivery of energy is terminated by an operator with or without a time period after the heart rate drops below the elevated level or after loss of capture of the heart of the subject.
According to some embodiments, the method additional includes providing data related to the heart rate of the subject to at least one output. In some embodiments, the at least one output comprises a display (e.g., display, other monitor, etc.). In some embodiments, data related to the heart rate of the subject are provided via and processed by an electrophysiology (EP) recording system. In some embodiments, delivering ablative energy to the ablation electrode comprises delivering radiofrequency (RF) energy.
According to some embodiments, a system for delivering energy to targeted cardiac tissue of a subject and for confirming successful ablation of said targeted cardiac tissue comprises a catheter comprising a high-resolution electrode along a distal end of the catheter, an energy delivery module (e.g., generator) comprising a processor, the energy delivery module being configured to operatively couple to the catheter, wherein the energy delivery module is configured to energize the electrode to selectively ablate targeted cardiac tissue adjacent the electrode, wherein the energy delivery module is configured to couple to a pacemaker for selectively pacing cardiac tissue in order to selectively increase a heart rate of the subject, wherein the system is configured, via a predetermined pacing signal provided to the catheter by the pacemaker, to increase the heart rate of the subject from a baseline level to an elevated level, the predetermined pacing signal comprising a pacing level greater than a pre-ablation pacing threshold level and less than a post-ablation pacing threshold level, wherein a heart rate of the subject is at the elevated level before the post-ablation pacing threshold level is achieved, wherein a heart rate of the subject falls below the elevated level once the high-resolution electrode has ablated adjacent tissue to a target therapeutic level, and wherein the processor is configured to terminate the delivery of energy to the electrode after the subject's heart rate drops below the elevated level.
According to some embodiments, the pacemaker is integral to the energy delivery module. In some embodiments, the pacemaker is separate from the energy delivery module. In some embodiments, the pacemaker is included in the system. In some configurations, the pacemaker is not included in the system.
According to some embodiments, the energy delivery module is configured to deliver radiofrequency (RF) energy to the electrode. In some embodiments, the electrode comprises a high-resolution electrode having a distal portion and a proximal portion, the distal and proximal portions of the high-resolution electrode being operatively coupled to each other using at least one filtering element. In some embodiments, the at least one filtering element comprises a capacitor.
According to some embodiments, the catheter further comprises at least one additional mapping electrode. In some embodiments, the energy delivery module comprises a radiofrequency (RF) generator. In some embodiments, the energy delivery module comprises at least one filter, the at least one filter being configured to isolate a signal relating to the localized heart rate signal measured using the high-resolution mapping electrode.
According to some embodiments, the predetermined pacing level is 5 to 20 milliamps (mA) (e.g., 5-6, 6-7, 7-8, 8-9, 9-10, 10-11, 11-12, 12-13, 13-14, 14-15, 15-16, 16-17, 17-18, 18-19, 19-20 mA, etc.). In some embodiments, the pacing threshold is 10 to 15 milliamps (mA). In some embodiments, the elevated level of the heart rate upon pacing the cardiac tissue at the predetermined pacing level is 100 to 200 beats per minute (bpm) (e.g., e.g., 100-105, 105-110, 110-115, 115-120, 120-125, 125-130, 130-135, 135-140, 140-145, 145-150, 150-155, 155-160, 160-165, 165-170, 170-175, 175-180, 180-185, 185-190, 190-195, 195-200 bpm, etc.). In some embodiments, the elevated level of the heart rate upon pacing the cardiac tissue at the predetermined pacing level is 120 to 150 beats per minute (bpm). In some embodiments, the pre-ablation pacing threshold level is 0.1 to 3 milliamps (mA) (e.g., 0.1-0.2, 0.2-0.3, 0.3-0.4, 0.4-0.5, 0.5-0.6, 0.6-0.7, 0.7-0.8, 0.8-0.9, 0.9-1.0, 1.0-1.1, 1.1-1.2, 1.2-1.3, 1.3-1.4, 1.4-1.5, 1.5-1.6. 1.6-1.7, 1.7-1.8, 1.8-1.9, 1.9-2, 2-2.5, 2.5-3 mA, etc.). In some embodiments, the pre-ablation pacing threshold level is 0.5 to 2 milliamps (mA). In some embodiments, the post-ablation pacing threshold level is greater than 10 milliamps (mA). In some embodiments, the post-ablation pacing threshold level is greater than 20 milliamps (mA).
According to some embodiments, the processor is configured to terminate the delivery of energy to the electrode as soon as the heart rate drops below the elevated level or after loss of capture of the heart of the subject. In some embodiments, the processor is configured to terminate the delivery of energy to the electrode following a pre-determined time period after the heart rate drops below the elevated level or after loss of capture of the heart of the subject. In some embodiments, the predetermined time period comprises 0.5 to 10 seconds (e.g., 0.5-1, 1-2, 2-3, 3-4, 4-5, 5-6, 6-7, 7-8, 8-9, 9-10 seconds, values between the foregoing ranges, etc.). In some embodiments, the predetermined time period comprises 1 to 5 seconds.
According to some embodiments, the system is configured so that delivery of energy is terminated by an operator with or without a time period after the heart rate drops below the elevated level or after loss of capture of the heart of the subject. In some embodiments, the system further comprises at least one output configured to receive data related to the subject's heart rate. In some embodiments, the at least one output comprises a display (e.g., monitor, other display, etc.). In some embodiments, the at least one output is integrated within the system. In other configurations, the at least one output is separate from the system.
According to some embodiments, data related to the subject's heart rate are provided via and processed by an EP recording system. In some embodiments, the post-ablation pacing threshold level is greater than 10 milliamps (mA). In some arrangements, the post-ablation pacing threshold level is greater than 20 milliamps (mA).
According to some embodiments, an energy delivery module (e.g., a generator) configured to deliver ablative energy to targeted cardiac tissue of a subject and for confirming successful ablation of said targeted cardiac tissue includes a processor for regulating the delivery of ablative energy, wherein the energy delivery module is configured to operatively couple to a catheter, wherein the energy delivery module is configured to energize an electrode positioned along a distal end of the catheter to selectively ablate targeted cardiac tissue adjacent the electrode, wherein the energy delivery module is configured to couple to a pacemaker for selectively pacing cardiac tissue in order to attain capture of the heart of the subject, wherein the processor is configured, via a predetermined pacing signal provided to the catheter by a pacemaker, to increase the heart rate of the subject from a baseline level to an elevated level, the predetermined pacing signal comprising a pacing level greater than a pre-ablation pacing threshold level, and wherein the processor is configured to terminate the delivery of energy to the electrode after loss of capture of the heart of the subject.
According to some embodiments, the energy delivery module further comprises a pacemaker. In some embodiments, the pacemaker is integrated within the module. In some embodiments, the pacemaker is separate from the module.
According to some embodiments, a kit for delivering ablative energy to targeted cardiac tissue of a subject and for confirming successful ablation of said targeted cardiac tissue comprises a catheter including a high-resolution electrode (e.g., a split-tip electrode) along a distal end of the catheter, and an energy delivery module comprising a processor, wherein the processor is configured to regulate the delivery of ablative energy, wherein the energy delivery module is configured to operatively couple to the catheter, wherein the energy delivery module is configured to energize the electrode positioned along a distal end of the catheter to selectively ablate targeted cardiac tissue adjacent the electrode, wherein the energy delivery module is configured to couple to a pacemaker for selectively pacing cardiac tissue in order to attain capture of the heart of the subject, wherein the processor is configured, via a predetermined pacing signal provided to the catheter by a pacemaker, to increase the heart rate of the subject from a baseline level to an elevated level, the predetermined pacing signal comprising a pacing level greater than a pre-ablation pacing threshold level, and wherein the processor is configured to terminate the delivery of energy to the electrode after loss of capture of the heart of the subject.
According to some embodiments, the kit further comprises the pacemaker. In some embodiments, the pacemaker is integrated within the energy delivery module. In other configurations, the pacemaker is separate from the energy delivery module. In one embodiment, the energy delivery module is configured to receive (e.g., via a port, coupling, other wired connection, a wireless connection, etc.) a pacemaker.
According to some embodiments, a processor configured for use with an energy delivery module configured to deliver ablative energy to targeted cardiac tissue of a subject and for confirming successful ablation of said targeted cardiac tissue is configured to regulate the delivery of ablative energy from an energy delivery module to an electrode, wherein the energy delivery module is configured to operatively couple to a catheter comprising the electrode, wherein the energy delivery module is configured to energize the electrode positioned along a distal end of the catheter to selectively ablate targeted cardiac tissue adjacent the electrode, wherein the processor is configured to couple to a pacemaker for selectively pacing cardiac tissue in order to attain capture of the heart of the subject, wherein the processor is configured, via a predetermined pacing signal provided to the catheter by a pacemaker, to increase the heart rate of the subject from a baseline level to an elevated level, the predetermined pacing signal comprising a pacing level greater than a pre-ablation pacing threshold level, and wherein the processor is configured to terminate the delivery of energy to the electrode after loss of capture of the heart of the subject. According to some embodiments, the processor is directly or indirectly coupled to a pacemaker.
According to some embodiments, a generator configured to deliver ablative energy to targeted cardiac tissue of a subject and for confirming successful ablation of said targeted cardiac tissue comprises an energy delivery module configured to generate ablative energy for delivery to an ablation device, and a processor configured to regulate the delivery of ablative energy from the energy delivery module to an electrode of the ablation device, wherein ablative energy generated by the energy delivery module is delivered to the electrode assembly, wherein the energy delivery module is configured to couple to a pacemaker for selectively pacing cardiac tissue in order to attain capture of the heart of the subject, wherein the processor is configured, via a predetermined pacing signal provided to the catheter by a pacemaker, to increase the heart rate of the subject from a baseline level to an elevated level, the predetermined pacing signal comprising a pacing level greater than a pre-ablation pacing threshold level, and wherein the processor is configured to terminate the delivery of energy to the electrode after loss of capture of the heart of the subject.
According to some embodiments, the energy delivery module is configured to generated radiofrequency (RF) energy. In some embodiments, the processor and the energy delivery module are located within a single housing or enclosure. In some embodiments, the processor and the energy delivery module are located within separate housings or enclosures. In some embodiments, the generator includes the pacemaker. In some embodiments, the pacemaker is integral to the energy delivery module. In other arrangements, the pacemaker is separate from the energy delivery module.
According to some embodiments, the electrode comprises a high-resolution electrode (e.g., split-tip electrode). In some embodiments, the high resolution electrode comprises a distal portion and a proximal portion, the distal and proximal portions of the high-resolution electrode being operatively coupled to each other using at least one filtering element. In some embodiments, the at least one filtering element comprises a capacitor.
These and other features, aspects and advantages of the present application are described with reference to drawings of certain embodiments, which are intended to illustrate, but not to limit, the concepts disclosed herein. The attached drawings are provided for the purpose of illustrating concepts of at least some of the embodiments disclosed herein and may not be to scale.
According to some embodiments, successful electrophysiology procedures require precise knowledge about the anatomic substrate being targeted. Additionally, it may be desirable to evaluate the outcome of an ablation procedure within a short period of time after the execution of the procedure (e.g., to confirm that the desired clinical outcome was achieved). Typically, ablation catheters include only regular mapping electrodes (e.g., ECG electrodes). However, in some embodiments, it may be desirable for such catheters to incorporate high-resolution mapping capabilities. In some embodiments, high-resolution mapping electrodes can provide more accurate and more detailed information about the anatomic substrate and about the outcome of ablation procedures. For example, such high-resolution mapping electrodes can allow the electrophysiology (EP) practitioner to evaluate the morphology of electrograms, their amplitude and width and/or to determine changes in pacing thresholds. According to some arrangements, morphology, amplitude and/or pacing threshold are accepted as reliable EP markers that provide useful information about the outcome of ablation. Thus, high-resolution electrodes are defined as any electrode(s) capable of delivering ablative or other energy to tissue capable of transferring heat to/from such tissue, while being capable of obtaining accurate mapping data of adjacent tissue, and include, without limitation, split-tip RF electrodes, other closely oriented electrodes or electrode portions and/or the like.
Several embodiments disclosed herein are particularly advantageous because they include one, several or all of the following benefits or advantages: reducing proximal edge heating, reducing the likelihood of char formation, providing for feedback that may be used to adjust ablation procedures in real time, providing noninvasive temperature measurements, providing safer and more reliable ablation procedures, providing for confirmation that a targeted region of tissue being treated has been properly ablated (e.g., using confirmation related to capture of the heart) and/or the like.
According to some embodiments, various implementations of electrodes (e.g., radiofrequency or RF electrodes) that can be used for high-resolution mapping are disclosed herein. For example, as discussed in greater detail herein, an ablation or other energy delivery system can comprise a high-resolution-tip design, wherein the energy delivery member (e.g., radiofrequency electrode) comprises two or more separate electrodes or electrode portions. As also discussed herein, in some embodiments, such separate electrodes or electrode portions can be advantageously electrically coupled to each other (e.g., to collectively create the desired heating or ablation of targeted tissue).
In some embodiments, the medical instrument 20 is operatively coupled to one or more devices or components. For example, as depicted in
With continued reference to the schematic of
According to some embodiments, the energy delivery module 40 includes a processor 46 (e.g., a processing or control unit) that is configured to regulate one or more aspects of the treatment system 10. The module 40 can also comprise a memory unit or other storage device 48 (e.g., computer readable medium) that can be used to store operational parameters and/or other data related to the operation of the system 10. In some embodiments, the processor 46 is configured to automatically regulate the delivery of energy from the energy generation device 42 to the energy delivery member 30 of the medical instrument 20 based on one or more operational schemes. For example, energy provided to the energy delivery member 30 (and thus, the amount of heat transferred to or from the targeted tissue) can be regulated based on, among other things, the detected temperature of the tissue being treated.
According to some embodiments, the energy delivery system 10 can include one or more temperature detection devices, such as, for example, reference temperature devices (e.g., thermocouples, thermistors, etc.) and/or the like. For example, in some embodiments, the device further comprises a one or more temperature sensors or other temperature-measuring devices to help determine a peak (e.g., high or peak, low or trough, etc.) temperature of tissue being treated. In some embodiments, the temperature sensors (e.g., thermocouples) located at, along and/or near the ablation member (e.g., RF electrode) can help with the determination of whether contact is being made between the ablation member and targeted tissue (and/or to what degree such contact is being made). In some embodiments, such peak temperature is determined without the use of radiometry.
With reference to
In some embodiments, the distal electrode or electrode portion 30A is 0.5 mm long. In other embodiments, the distal electrode or electrode portion 30A is between 0.1 mm and 1 mm long (e.g., 0.1-0.2, 0.2-0.3, 0.3-0.4, 0.4-0.5, 0.5-0.6, 0.6-0.7, 0-0.8, 0.8-0.9, 0.9-1 mm, values between the foregoing ranges, etc.). In other embodiments, the distal electrode or electrode portion 30A is greater than 1 mm in length, as desired or required. In some embodiments, the proximal electrode or electrode portion 30B is 2 to 4 mm long (e.g., 2-2.5, 2.5-3, 3-3.5, 3.5-4 mm, lengths between the foregoing, etc.). However, in other embodiments, the proximal electrode portion 30B is greater than 4 mm (e.g., 4-5, 5-6, 6-7, 7-8, 8-9, 9-10 mm, greater than 10 mm, etc.) or smaller than 1 mm (e.g., 0.1-0.5 0.5-1, 1-1.5, 1.5-2 mm, lengths between the foregoing ranges, etc.), as desired or required. In embodiments where the high-resolution electrodes are located on catheter shafts, the length of the electrodes can be 1 to 5 mm (e.g., 1-2, 2-3, 3-4, 4-5 mm, lengths between the foregoing, etc.). However, in other embodiments, the electrodes can be longer than 5 mm (e.g., 5-6, 6-7, 7-8, 8-9, 9-10, 10-15, 15-20 mm, lengths between the foregoing, lengths greater than 20 mm, etc.), as desired or required.
As noted above, the use of a high-resolution tip design can permit a user to simultaneously ablate or otherwise thermally treat targeted tissue and map (e.g., using high-resolution mapping) in a single configuration. Thus, such systems can advantageously permit precise high-resolution mapping (e.g., to confirm that a desired level of treatment occurred) during a procedure. In some embodiments, the high-resolution tip design that includes two electrodes or electrode portions 30A, 30B can be used to record a high-resolution bipolar electrogram. For such purposes, the two electrodes or electrode portions can be connected to the inputs of an EP recorder. In some embodiments, a relatively small separation distance (e.g., gap G) between the electrodes or electrode portions 30A, 30B enables high-resolution mapping.
In some embodiments, a medical instrument (e.g., a catheter) 20 can include three or more electrodes or electrode portions (e.g., separated by gaps), as desired or required. Additional details regarding such arrangements are provided below. According to some embodiments, regardless of how many electrodes or electrode portions are positioned along a catheter tip, the electrodes or electrode portions 30A, 30B are radiofrequency electrodes and comprise one or more metals, such as, for example, stainless steel, platinum, platinum-iridium, gold, gold-plated alloys and/or the like.
According to some embodiments, as illustrated in
According to some embodiments, a separator 34 is positioned within the gap G, between the adjacent electrodes or electrode portions 30A, 30B, as depicted in
As noted above with respect to the gap G separating the adjacent electrodes or electrode portions, the insulating separator 34 can be 0.5 mm long. In other embodiments, the length of the separator 34 can be greater or smaller than 0.5 mm (e.g., 0.1-0.2, 0.2-0.3, 0.3-0.4, 0.4-0.5, 0.5-0.6, 0.6-0.7, 0.7-0.8, 0.8-0.9, 0.9-1.0 mm, values between the foregoing ranges, less than 0.1 mm, greater than 1 mm, etc.), as desired or required.
According to some embodiments, as discussed in greater detail herein, to ablate or otherwise heat or treat targeted tissue of a subject successfully with the high-resolution tip electrode design, such as the one depicted in
As shown in
As shown in
As depicted in
According to some embodiments, a catheter can include a high-resolution-tip electrode design that includes one or more gaps in the circumferential direction (e.g., radially), either in addition to or in lieu of gaps in the longitudinal direction. One embodiment of a system 300 comprising one or more electrodes 310A, 310B is illustrated in
With continued reference to
Regardless of how the circumferential electrode sections are designed and oriented, electrically insulating gaps G can be provided between adjacent sections to facilitate the ability to use the electrode to conduct high-resolution mapping, in accordance with the various embodiments disclosed herein. Further, as illustrated in the embodiment of
In alternative embodiments, the various embodiments of a high-resolution tip design disclosed herein, or variations thereof, can be used with a non-irrigated system or a closed-irrigation system (e.g., one in which saline and/or other fluid is circulated through or within one or more electrodes to selectively remove heat therefrom). Thus, in some arrangements, a catheter can include two or more irrigation tubes or conduits. For example, one tube or other conduit can be used to deliver fluid toward or near the electrodes, while a second tube or other conduit can be used to return the fluid in the reverse direction through the catheter.
According to some embodiments, a high-resolution tip electrode is designed to balance the current load between the various electrodes or electrode portions. For example, if a treatment system is not carefully configured, the electrical load may be delivered predominantly to one or more of the electrodes or electrode portions of the high-resolution tip system (e.g., the shorter or smaller distal electrode or electrode portion). This can lead to undesirable uneven heating of the electrode, and thus, uneven heating (e.g., ablation) of the adjacent tissue of the subject. Thus, in some embodiments, one or more load balancing configurations can be used to help ensure that the heating along the various electrodes or electrode portions of the system will be generally balanced. As a result, the high-resolution tip design can advantageously function more like a longer, single electrode, as opposed to two or more electrodes that receive an unequal electrical load (and thus, deliver an unequal amount of heat or level of treatment to the subject's targeted tissue).
One embodiment of a configuration that can be used to balance the electrical current load delivered to each of the electrodes or electrode portions in a high-resolution tip design is schematically illustrated in
In the embodiment that is schematically depicted in
With continued reference to
In some embodiments, a series impedance of 3Ω across the electrodes or electrode portions 30A, 30B is sufficiently low when compared to the impedance of the conductor 82 (e.g., wire, cable, etc.), which can be about 5-10Ω, and the impedance of tissue, which can be about 100Ω, such that the resulting tissue heating profile is not negatively impacted when the system is in use. Thus, in some embodiments, a filtering element is selected so that the series impedance across the electrodes or electrode portions is lower than the impedance of the conductor that supplies RF energy to the electrodes. For example, in some embodiments, the insertion impedance of the filtering element is 50% of the conductor 82 impedance, or lower, or 10% of the equivalent tissue impedance, or lower.
In some embodiments, a filtering element (e.g., capacitor a filter circuit such as the one described herein) can be located at a variety of locations of the device or accompanying system. For example, in some embodiments, the filtering element is located on or within a catheter (e.g., near the distal end of the catheter, adjacent the electrode, etc.). In other embodiments, however, the filtering element is separate of the catheter. For instance, the filtering element can be positioned within or along a handle to which the catheter is secured, within the generator or other energy delivery module, within a separate processor or other computing device or component and/or the like).
Similarly, with reference to the schematic of
In embodiments where the high-resolution-tip design (e.g.,
As discussed above, the relatively small gap G between the adjacent electrodes or electrode portions 30A, 30B can be used to facilitate high-resolution mapping of the targeted tissue. For example, with continued reference to the schematic of
According to some arrangements, the high-resolution-tip electrode embodiments disclosed herein are configured to provide localized high-resolution electrogram. For example, the electrogram that is obtained using a high-resolution-tip electrode, in accordance with embodiments disclosed herein, can provide electrogram data (e.g., graphical output) 400a, 400b as illustrated in
With continued reference to
In some embodiments, a comparison is made between such a baseline amplitude (A1) relative to an electrogram amplitude (A2) at a tissue location being tested or evaluated. A ratio of A1 to A2 can be used to provide a quantitative measure for assessing the likelihood that ablation has been completed. In some arrangements, if the ratio (i.e., A1/A2) is above a certain minimum threshold, then the user can be informed that the tissue where the A2 amplitude was obtained has been properly ablated. For example, in some embodiments, adequate ablation or treatment can be confirmed when the A1/A2 ratio is greater than 1.5 (e.g., 1.5-1.6, 1.6-1.7, 1.7-1.8, 1.8-1.9, 1.9-2.0, 2.0-2.5, 2.5-3.0, values between the foregoing, greater than 3, etc.). However, in other embodiments, confirmation of ablation can be obtained when the ratio of A1/A2 is less than 1.5 (e.g., 1-1.1, 1.1-1.2, 1.2-1.3, 1.3-1.4, 1.4-1.5, values between the foregoing, etc.).
According to some embodiments, an ablation system is configured to operatively couple to a pacemaker or related system that is configured to selectively pace or increase the heart rate of a subject. As discussed in greater detail herein, the use of such pacing can be used to confirm whether targeted tissue (e.g., cardiac tissue) has been properly ablated. Accordingly, such a system and related method can provide the user with information for assessing the success of a treatment procedure. For example, data provided by the system can be used to determine if the targeted tissue has been properly ablated. Thus, the various systems, devices and methods disclosed herein can be used to ensure that a desired or required level of treatment to targeted tissue has been accomplished. The confirmation and other feedback provided by the various systems, devices and methods disclosed herein can be used in addition to or in lieu of any other protocols for confirming successful treatment of targeted tissue.
According to some embodiments, an energy delivery module (e.g., a radiofrequency generator or other energy delivery generator) of an ablation system can be configured to be coupled to a pacemaker device or system. In some embodiments, such a pacemaker comprises a separate device or system that is separate and distinct of the energy delivery module and/or other components of the ablation system. However, in other configurations, the pacemaker device or system can be integrated within the energy delivery module and/or any other component of the system.
Regardless of whether the pacemaker device or system is integrated within or separate from the energy delivery module (e.g., radiofrequency generator) and/or any other component of an ablation system, such a pacemaker device or system can be configured to selectively pace cardiac tissue or increase a heart rate of a subject being treated. According to some embodiments, such pacing or an increase in heart rate is performed for purposes of confirming successful ablation of targeted tissue (e.g., atrial, ventricular and/or other cardiac tissue), as discussed in greater detail herein. However, the use of pacing can be performed for one or more other purposes as well, either in addition to or in lieu of confirmation of ablation, as desired or required.
In some embodiments, the heart of the subject is selectively paced (e.g., the heart rate of the subject is increased) to a desired level by delivering a pacing signal to the heart via one or more electrodes. For example, as illustrated schematically in
With continued reference to
As shown in
In some embodiments, once operatively coupled to an ablation/monitoring system 2000, a pacemaker device or system 2400 can be used to provide a pacing current to the catheter or other medical instrument 2220 in order to selectively increase the heart rate of the subject's heart. For example, in some embodiments, the heart rate of a subject can be increased from a baseline heart rate to 100-200 beats per minute, bpm, (e.g., 100-105, 105-110, 110-115, 115-120, 120-125, 125-130, 130-135, 135-140, 140-145, 145-150, 150-160, 160-170, 170-180, 180-190, 190-200 bpm, 120-150 bpm, frequencies between the foregoing, etc.) by delivering a pacing signal to the catheter.
Further, according to some embodiments, the pacing current generated by the pacemaker device or system 2400 is directed to and routed, at least partially, through the energy delivery module (e.g., RF generator) 2240. In some embodiments, the energy delivery module 2240 comprises a filter section 2246 through which the pacing current passes. According to some configurations, the filter section 2246 of the energy delivery module 2240 comprises low insertion impedance EGM filters that facilitate the delivery of the pacing current to the catheter or other medical instrument 2220 coupled to the energy delivery module 2240. Such filters can permit the system 2000 to deliver energy (e.g., radiofrequency energy, other ablative energy, etc.) to the electrode(s) of the catheter 2220 while simultaneously providing a desired pacing current to such electrode(s).
With continued reference to the schematic of
As discussed with reference to other embodiments herein, the catheter or other medical instrument 2220 that operatively couples to the energy delivery module 2240 can include a high-resolution electrode design. For example, in some embodiments, the catheter comprises an electrode that is configured to obtain high-resolution mapping data (e.g., when ablative energy is not being delivered to the electrode), in accordance with the various embodiments disclosed herein, or variations thereof. For example, a filtering element or other feature can advantageously permit the electrode along the distal end of the catheter or other medical instrument 2220 to obtain high resolution mapping data before and/or after ablative energy (e.g., radiofrequency energy) has been delivered to the catheter or other medical instrument 2220. In some embodiments, the design of such a high-resolution electrode assembly can permit a user to obtain and use accurate mapping data associated with the specific location of the electrode.
As schematically illustrated in
In some embodiments, any of the cardiac pacing concepts disclosed herein (e.g., the ability to provide pacing currents to a catheter or other medical instrument, the ability to pace or increase the heart rate of a subject prior to or during a cardiac treatment procedure, etc.) can be used with catheters or other medical instruments that do not include high-resolution mapping electrodes or related features. Thus, the pacing concepts (e.g., and the related confirmation of ablation of targeted tissue) can be incorporated into any energy delivery and/or mapping technologies, regardless of whether they are specifically described or otherwise disclosed herein.
According to some embodiments, pacing currents can be provided to the electrode or other energy delivery device of a catheter (or other medical instrument). In some arrangements, the pacing current that is provided to the electrode or other energy delivery device is greater than the pre-ablation pacing threshold level, but lower than the post-ablation pacing threshold level. For example, once paced (e.g., using the current or signal provided by the pacemaker device or system 2400), the subject's heart will be paced (e.g., the subject's heart rate will increase to an elevated heart rate frequency or level). As discussed in greater detail herein, for instance, the pacemaker signal can increase the subject's heart rate to 100-150 beats per minute (bpm), e.g., 100-105, 105-110, 110-115, 115-120, 120-125, 125-130, 130-135, 135-140, 140-145, 145-150 bpm, value between the foregoing ranges, etc.). In other embodiments, the pacing can increase a subject's heart rate to levels exceeding 150 bpm (e.g., 150-160, 160-170, 170-180 bpm, values between the foregoing ranges, values greater than 180 bpm, etc.) or less than 100 bpm (e.g., 70-75, 75-80,80-85, 85-90, 90-95, 95-100 bpm, values between the foregoing ranges, values less than 70 bpm, etc.), as desired to required.
According to some embodiments, as indicated above, the pacing current provided by the pacemaker device or system 2400 coupled to (or integrated with) the energy delivery module (e.g., the RF generator) 2240 will exceed a pre-ablation pacing threshold. In other words, the pacing current will be configured to stimulate the subject's heart to a desired elevated rate or level and will also be configured to surpass the pacing threshold at which the targeted tissue of the subject will be ablated or otherwise heat-treated to a desired level.
In some embodiments, the pacing current provided by the pacemaker device or system 2400 is greater than 15 milliamps (mA). For example, the pacing current provided by the pacemaker device or system is 15-20 milliamps (mA), e.g., 15-16, 16-17, 17-18, 18-19, 19-20 mA, currents between the foregoing ranges, etc. In other embodiments, the pacing current provided by the pacemaker device or system is less than 15 mA (e.g., 10-11, 11-12, 12-13, 13-14, 14-15 mA, currents between the foregoing ranges, etc.) or greater than 20 mA, (e.g., 20-21, 21-22, 22-23, 23-24, 24-25, 25-30 mA, currents between the foregoing ranges, currents greater than 30 mA, etc.), as desired or required. In some embodiments, the pacing current provided by the pacemaker device or system is 5 to 20 mA (e.g., 10-15 mA).
Regardless of the exact pacing current provided to the electrode(s) or electrode portion(s) of the catheter or other medical instrument by the pacemaker device or system, the heart rate of the subject being treated will increase above the subject's baseline (e.g., normal) heart rate. In some embodiments, the formation of a lesion or the completion of heat treatment of the targeted tissue will cause the pacing threshold to increase considerably, from pre-ablation levels (e.g. 1 to 5 mA) to post-ablation levels (e.g. 15 to 20 mA, or greater). By way of example, and without limitation, in some embodiments, it is possible that the pre-ablation pacing threshold is approximately 1 mA and the post-ablation pacing threshold is approximately 20 mA. In such circumstances, application of pacing currents of 10 mA would produce “heart capture,” meaning an increase of the heart rate to the rate programmed on pacemaker device or system 2400. With successful ablation treatment, as the pacing threshold increases, the user will observe the cessation of pacing signals being propagated through such a lesion or treated tissue, as the post-ablation pacing threshold exceeds the pacing current amplitude (e.g., in the specific, non-limiting example provided above, 20 mA is greater than 10 mA). As a result, the heart rate of the subject being treated will drop to a level below the elevated heart rate induced by the pacing signal generated by the pacemaker device or system. The loss of such an elevated pacing rate of cardiac tissue is referred to as “loss of capture,” providing another form of confirmation to a user that the targeted tissue has been properly treated (e.g., ablated).
In some embodiments, such confirmation of adequate ablation of tissue can help prevent overheating of targeted tissue, as the user is notified in a prompt manner that loss of capture (e.g., or a desired level of tissue ablation) has been attained. As a result, the likelihood of charring or overheating of targeted tissue can be prevented. This can help ensure that undesirable damage to the targeted tissue is avoided and/or that damage to tissue surrounding or adjacent to the targeted tissue is not inadvertently harmed.
The use of high-resolution electrode(s) or electrode portion(s) further enhances the pacing data obtained by the system, in accordance with several embodiments. For example, in some embodiments, the ability of high-resolution electrode(s) or electrode portion(s), in accordance with the various configurations described herein or variations thereof to pace the cardiac tissue located in its immediate vicinity ensures that the devices, systems, methods and techniques disclosed herein have high specificity. As a result, pacing of far-field tissues is avoided. Therefore, the technique advantageously monitors the localized effects of cardiac ablation. As a result, the cardiac data obtained using the system are specific to the anatomical region adjacent the high-resolution electrode, providing a more accurate representation of the condition of the targeted tissue. Thus, the likelihood of overheating targeted tissue is advantageously reduced.
According to some embodiments, the pre-ablation pacing threshold is greater than 1 or 2 milliamps (mA). For example, the pre-ablation pacing threshold is 1-5 mA (e.g., 1-1.5, 1.5-2, 2-2.5, 2.5-3, 3-3.5, 3.5-4, 4-4.5, 4.5-5 mA, values between the foregoing ranges, etc.). However, in other embodiments, the pre-ablation pacing threshold is greater than 5 mA (e.g., 5-6, 6-7, 7-8 mA, values between the foregoing ranges, greater than 8 mA, etc.) or less than 1 mA (e.g., 0.1-0.2, 0.2-0.3, 0.3-0.4, 0.4-0.5, 0.5-0.6, 0.6-0.7, 0.7-0.8, 0.8-0.9, 0.9-1 mA, values between the foregoing ranges, values less than 0.1 mA, etc.), as desired or required. In some embodiments, the pre-ablation pacing threshold is 0.1 to 5 mA (e.g., 0.5-2 mA). In addition, in some configurations, the post-ablation pacing threshold is greater than 10 milliamps (mA). For example, the post-ablation pacing threshold is 10-15 mA (e.g., 10-11, 11-12, 12-13, 13-14, 14-15 mA, values between the foregoing ranges, values greater than 15 mA, etc.). However, in other embodiments, the post-ablation pacing threshold is less than 10 mA (e.g., 5-6, 6-7, 7-8, 8-9, 9-10 mA, values between the foregoing ranges, less than 5 mA, etc.), as desired or required. Conversely, in other embodiments, the post-ablation pacing threshold may exceed 20 mA. In some embodiments, the post-ablation pacing threshold exceeds 10 mA or 20 mA.
According to some arrangements, once loss of capture is achieved (e.g., confirmation of ablation or desired/required heat treatment of targeted tissue is received by and/or communicated to a user), the system 2000 can be configured to terminate the delivery of RF (or other energy) from the energy delivery module 2240 (e.g., RF generator) to the catheter or other medical instrument 2220, either immediately or following a particular time period. In some embodiments, a processor or other control unit of the energy delivery module (and/or any other processor or control unit external to the energy delivery module or system) can be configured to automatically terminate (or alter, e.g., modulate or slow down) the delivery of RF or other energy to the catheter or other medical instrument once loss of capture has been attained.
In other embodiments, however, a processor or other portion of the system (and/or operatively coupled to the system) can be configured to automatically terminate (or alter) a delivery of energy (e.g., RF) to the catheter or other medical instrument after a certain time period after loss of capture has been attained. For example, according to some arrangements, the processor or other control unit of the energy delivery module (e.g., RF generator) and/or any other processor or control unit operatively coupled to the system 2000 can be configured to permit the delivery of energy to the electrode(s) or other energy delivery member of the catheter or other medical instrument for 0.5-5 seconds (e.g., 0.5-1, 1-1.5, 1.5-2, 2-2.5, 2.5-3, 3-3.5, 3.5-4, 4-4.5, 4.5-5 seconds, time periods between the foregoing ranges, etc.) after loss of capture has been achieved. In other embodiments, the delivery of energy can continue for a time period greater than 5 seconds after loss of capture (e.g., 5-6, 6-7, 7-8, 8-9, 9-10, 10-15, 15-20, 20-30 seconds, time periods between the foregoing ranges, greater than 30 seconds, etc.). In some embodiments, such a protocol or configuration can help ensure that proper ablation has been accomplished.
According to some embodiments, the confirmation of completed ablation using the pacing of cardiac tissue and the subsequent loss of capture can be used either in lieu of or in addition to other metrics, techniques, tools and/or methods, such as, for example, ECG amplitude reductions, visual evidence of lesion formation (e.g., fluoro and/or ultrasound imaging, other imaging, etc.) and/or the like, regardless of whether such confirmation tools are specifically disclosed herein. For example, in some embodiments, the confirmation procedures relating to pacing and loss of capture are used as the sole or primary method of confirming proper ablation of targeted tissue. However, in other configurations, the use of such techniques and methods can be used to confirm or otherwise validate results and data obtained using one or more other techniques or methods, as desired or required.
With continued reference to the schematic of
According to some embodiments, due to the nature of the high-resolution-tip electrode systems that are used to create a more complete and comprehensive map of targeted tissue, in accordance with the various high-resolution-tip systems and devices disclosed herein, additional information regarding the position of the roving catheter (and thus, the intermediate mapping locations) can be obtained and provided to the user during a procedure. For example, given the high-resolution mapping capabilities of such catheters, information can be obtained regarding the nature, type and other details regarding the tissue that is adjacent the electrode. In addition, as noted above, the high-resolution-tip embodiments disclosed herein can help determine whether a specific tissue region has been adequately ablated (e.g., see the disclosure above with reference to
In some embodiments, any of the high-resolution-tip electrode devices or systems disclosed herein can be used as stand-alone mapping systems to accurately assess the condition of a subject's targeted anatomical region, even with the use of a separate mapping system. For example, a user can move a high-resolution-tip electrode catheter or other medical instrument to various locations within a subject's anatomy to generate a detailed, accurate and complete electrical map, as desired or required.
As a result of the high-resolution mapping capabilities of the various high-resolution-tip electrode catheter devices and systems disclosed herein, an accurate map of the subject's targeted anatomical space or other region can be obtained. In addition, in view of the fact that such systems are also configured to advantageously ablate tissue, a more efficient and accurate treatment procedure can be attained. For example, in embodiments where one of the high-resolution-tip electrodes devices or systems disclosed herein is being use to map a subject's anatomy (e.g., atrium), either with or without the use of a separate (e.g., commercially-available mapping system), such a high-resolution-tip device or system can be used to also ablate tissue. This can facilitate and improve the execution of a treatment procedure. For example, the ability to use a single device to both map and ablate tissue permits a user to more expeditiously perform an overall assessment and treatment of a subject. In addition, the ability to create a more comprehensive map of the subject's tissue, allows a user to perform a subject treatment procedure with greater accuracy and precision. As discussed, this can help reduce the overall (and sometimes unnecessary) trauma to the subject, improve recovery and provide for better and effective treatment of the subject's disease. In addition, as noted above, the ability of the user to determine whether tissue has already been ablated or otherwise treated to a sufficient level can further improve the efficacy, efficiency and/or safety of a procedure.
In some embodiments, the system comprises various features that are present as single features (as opposed to multiple features). For example, in one embodiment, the system includes a single catheter that is configured to obtain high-resolution mapping of tissue. The system can include a single energy delivery module (e.g., a generator) for supplying ablative or other energy to the catheter. The system can further include a single processor that is configured to regulate the delivery of energy from the energy delivery module to the catheter. The catheter can include a split-tip electrode design and/or any other high-resolution configuration. The system can include a single pacemaker (e.g., that is integrated with or separate from the energy delivery module and/or any other component of the system) to selectively pace or increase the heartrate of a subject's heart.
According to some embodiments, the system consists essentially of a catheter that is configured to obtain high-resolution mapping of tissue, an energy delivery module (e.g., a RF or other generator) for supplying ablative or other energy to the catheter, and a processor that is configured to regulate the delivery of energy from the energy delivery module to the catheter. According to some embodiments, the system consists essentially of a catheter that is configured to obtain high-resolution mapping of tissue, an energy delivery module (e.g., a RF or other generator) for supplying ablative or other energy to the catheter, a processor that is configured to regulate the delivery of energy from the energy delivery module to the catheter and a pacemaker for selectively pacing the heart of the subject being treated.
In some embodiments, the system comprises one or more of the following: means for tissue modulation (e.g., an ablation or other type of modulation catheter or delivery device), means for generating energy (e.g., a generator or other energy delivery module), means for connecting the means for generating energy to the means for tissue modulation (e.g., an interface or input/output connector or other coupling member), means for increasing the heartrate of a subject being treated (e.g., using a pacemaker that is integrated with or separate from one or more components of the system), etc.
Any methods described herein may be embodied in, and partially or fully automated via, software code modules executed by one or more processors or other computing devices. The methods may be executed on the computing devices in response to execution of software instructions or other executable code read from a tangible computer readable medium. A tangible computer readable medium is a data storage device that can store data that is readable by a computer system. Examples of computer readable mediums include read-only memory, random-access memory, other volatile or non-volatile memory devices, CD-ROMs, magnetic tape, flash drives, and optical data storage devices.
In addition, embodiments may be implemented as computer-executable instructions stored in one or more tangible computer storage media. As will be appreciated by a person of ordinary skill in the art, such computer-executable instructions stored in tangible computer storage media define specific functions to be performed by computer hardware such as computer processors. In general, in such an implementation, the computer-executable instructions are loaded into memory accessible by at least one computer processor. The at least one computer processor then executes the instructions, causing computer hardware to perform the specific functions defined by the computer-executable instructions. As will be appreciated by a person of ordinary skill in the art, computer execution of computer-executable instructions is equivalent to the performance of the same functions by electronic hardware that includes hardware circuits that are hardwired to perform the specific functions. As such, while embodiments illustrated herein are typically implemented as some combination of computer hardware and computer-executable instructions, the embodiments illustrated herein could also be implemented as one or more electronic circuits hardwired to perform the specific functions illustrated herein.
The various systems, devices and/or related methods disclosed herein can be used to at least partially ablate and/or otherwise ablate, heat or otherwise thermally treat one or more portions of a subject's anatomy, including without limitation, cardiac tissue (e.g., myocardium, atrial tissue, ventricular tissue, valves, etc.), a bodily lumen (e.g., vein, artery, airway, esophagus or other digestive tract lumen, urethra and/or other urinary tract vessels or lumens, other lumens, etc.), sphincters, other organs, tumors and/or other growths, nerve tissue and/or any other portion of the anatomy. The selective ablation and/or other heating of such anatomical locations can be used to treat one or more diseases or conditions, including, for example, atrial fibrillation, mitral valve regurgitation, other cardiac diseases, asthma, chronic obstructive pulmonary disease (COPD), other pulmonary or respiratory diseases, including benign or cancerous lung nodules, hypertension, heart failure, denervation, renal failure, obesity, diabetes, gastroesophageal reflux disease (GERD), other gastroenterological disorders, other nerve-related disease, tumors or other growths, pain and/or any other disease, condition or ailment.
In any of the embodiments disclosed herein, one or more components, including a processor, computer-readable medium or other memory, controllers (for example, dials, switches, knobs, etc.), displays (for example, temperature displays, timers, etc.) and/or the like are incorporated into and/or coupled with (for example, reversibly or irreversibly) one or more modules of the generator, the irrigation system (for example, irrigant pump, reservoir, etc.) and/or any other portion of an ablation or other modulation system.
Although several embodiments and examples are disclosed herein, the present application extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses of the inventions and modifications and equivalents thereof. It is also contemplated that various combinations or subcombinations of the specific features and aspects of the embodiments may be made and still fall within the scope of the inventions. Accordingly, it should be understood that various features and aspects of the disclosed embodiments can be combine with or substituted for one another in order to form varying modes of the disclosed inventions. Thus, it is intended that the scope of the present inventions herein disclosed should not be limited by the particular disclosed embodiments described above, but should be determined only by a fair reading of the claims that follow.
While the embodiments disclosed herein are susceptible to various modifications, and alternative forms, specific examples thereof have been shown in the drawings and are herein described in detail. It should be understood, however, that the inventions are not to be limited to the particular forms or methods disclosed, but, to the contrary, the inventions are to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the various embodiments described and the appended claims. Any methods disclosed herein need not be performed in the order recited. The methods disclosed herein include certain actions taken by a practitioner; however, they can also include any third-party instruction of those actions, either expressly or by implication. For example, actions such as “advancing a catheter” or “delivering energy to an ablation member” include “instructing advancing a catheter” or “instructing delivering energy to an ablation member,” respectively. The ranges disclosed herein also encompass any and all overlap, sub-ranges, and combinations thereof. Language such as “up to,” “at least,” “greater than,” “less than,” “between,” and the like includes the number recited. Numbers preceded by a term such as “about” or “approximately” include the recited numbers. For example, “about 10 mm” includes “10 mm.” Terms or phrases preceded by a term such as “substantially” include the recited term or phrase. For example, “substantially parallel” includes “parallel.”
This application is a continuation application of U.S. application Ser. No. 15/179,861 filed Jun. 10, 2016, which is a continuation of PCT/US2015/061360, filed Nov. 18, 2015, which claims priority to U.S. Provisional Application No. 62/081,710, filed Nov. 19, 2014, and U.S. Provisional Application No. 62/193,547, filed Jul. 16, 2015, the entire contents of each of which are incorporated herein by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
4190053 | Sterzer | Feb 1980 | A |
4197860 | Sterzer | Apr 1980 | A |
4346716 | Carr | Aug 1982 | A |
4557272 | Carr | Dec 1985 | A |
4614514 | Carr et al. | Sep 1986 | A |
4632127 | Sterzer | Dec 1986 | A |
4647281 | Carr | Mar 1987 | A |
4686498 | Carr et al. | Aug 1987 | A |
4715727 | Carr | Dec 1987 | A |
4727874 | Bowers et al. | Mar 1988 | A |
4774961 | Carr | Oct 1988 | A |
4815479 | Carr | Mar 1989 | A |
4922912 | Watanabe | May 1990 | A |
4945912 | Langberg | Aug 1990 | A |
4955382 | Franz et al. | Sep 1990 | A |
4979510 | Franz et al. | Dec 1990 | A |
5073167 | Carr et al. | Dec 1991 | A |
RE33791 | Carr | Jan 1992 | E |
5105808 | Neuwirth et al. | Apr 1992 | A |
5149198 | Sterzer | Sep 1992 | A |
5176146 | Chive et al. | Jan 1993 | A |
5198776 | Carr | Mar 1993 | A |
5230349 | Landberg | Jul 1993 | A |
5282840 | Hudrlik | Feb 1994 | A |
5334141 | Carr et al. | Aug 1994 | A |
5334193 | Nardella | Aug 1994 | A |
5344435 | Turner et al. | Sep 1994 | A |
5354325 | Chive et al. | Oct 1994 | A |
5364336 | Carr | Nov 1994 | A |
5370676 | Sozanski et al. | Dec 1994 | A |
5383874 | Jackson et al. | Jan 1995 | A |
5385146 | Goldreyer et al. | Jan 1995 | A |
5398683 | Edwards et al. | Mar 1995 | A |
5456682 | Edwards et al. | Oct 1995 | A |
5462521 | Brucker et al. | Oct 1995 | A |
5485849 | Panescu et al. | Jan 1996 | A |
5487391 | Panescu | Jan 1996 | A |
5494042 | Panescu et al. | Feb 1996 | A |
5514130 | Baker | May 1996 | A |
5522815 | Durgin, Jr. et al. | Jun 1996 | A |
5531662 | Carr | Jul 1996 | A |
5540655 | Edwards et al. | Jul 1996 | A |
5546940 | Panescu et al. | Aug 1996 | A |
5549639 | Ross | Aug 1996 | A |
5562619 | Mirarchi et al. | Oct 1996 | A |
5577509 | Panescu et al. | Nov 1996 | A |
5582589 | Edwards et al. | Dec 1996 | A |
5582609 | Swanson et al. | Dec 1996 | A |
5584830 | Ladd | Dec 1996 | A |
5591125 | Edwards et al. | Jan 1997 | A |
5595183 | Swanson et al. | Jan 1997 | A |
5598848 | Swanson et al. | Feb 1997 | A |
5599295 | Rosen et al. | Feb 1997 | A |
5601088 | Swanson et al. | Feb 1997 | A |
5605157 | Panescu et al. | Feb 1997 | A |
5609157 | Panescu et al. | Mar 1997 | A |
5616268 | Carr | Apr 1997 | A |
5624392 | Saab | Apr 1997 | A |
5630425 | Panescu et al. | May 1997 | A |
5643197 | Brucker et al. | Jul 1997 | A |
5647870 | Kordis et al. | Jul 1997 | A |
5651780 | Jackson et al. | Jul 1997 | A |
5656030 | Hunjan et al. | Aug 1997 | A |
5658278 | Imran et al. | Aug 1997 | A |
5662110 | Carr | Sep 1997 | A |
5667488 | Lundquist et al. | Sep 1997 | A |
5672174 | Gough et al. | Sep 1997 | A |
5673704 | Marchlinski et al. | Oct 1997 | A |
5674191 | Edwards et al. | Oct 1997 | A |
5683381 | Carr et al. | Nov 1997 | A |
5683382 | Lenihan et al. | Nov 1997 | A |
5683384 | Gough et al. | Nov 1997 | A |
5685839 | Edwards et al. | Nov 1997 | A |
5685878 | Falwell et al. | Nov 1997 | A |
5688050 | Sterzer et al. | Nov 1997 | A |
5688266 | Edwards et al. | Nov 1997 | A |
5688267 | Panescu et al. | Nov 1997 | A |
5690614 | Carr et al. | Nov 1997 | A |
5702386 | Stern et al. | Dec 1997 | A |
5707369 | Vaitekunas et al. | Jan 1998 | A |
5711305 | Swanson et al. | Jan 1998 | A |
5712047 | Aso et al. | Jan 1998 | A |
5715832 | Koblish et al. | Feb 1998 | A |
5718701 | Shai et al. | Feb 1998 | A |
5722402 | Swanson et al. | Mar 1998 | A |
5722403 | McGee et al. | Mar 1998 | A |
5722416 | Swanson et al. | Mar 1998 | A |
5732698 | Swanson et al. | Mar 1998 | A |
5735846 | Panescu et al. | Apr 1998 | A |
5735847 | Gough et al. | Apr 1998 | A |
5740808 | Panescu et al. | Apr 1998 | A |
5743903 | Stern et al. | Apr 1998 | A |
5752518 | McGee et al. | May 1998 | A |
5755715 | Stem et al. | May 1998 | A |
5762786 | Oelbermann | Jun 1998 | A |
5769846 | Edwards et al. | Jun 1998 | A |
5769847 | Panescu et al. | Jun 1998 | A |
5779635 | Carr | Jul 1998 | A |
5779646 | Koblish et al. | Jul 1998 | A |
5782827 | Gough et al. | Jul 1998 | A |
5782828 | Chen et al. | Jul 1998 | A |
5782897 | Carr | Jul 1998 | A |
5792064 | Panescu et al. | Aug 1998 | A |
5792140 | Tu et al. | Aug 1998 | A |
5795303 | Swanson et al. | Aug 1998 | A |
5797903 | Swanson et al. | Aug 1998 | A |
5797905 | Fleischman et al. | Aug 1998 | A |
5800378 | Edwards et al. | Sep 1998 | A |
5800432 | Swanson | Sep 1998 | A |
5807309 | Lundquist et al. | Sep 1998 | A |
5807395 | Mulier et al. | Sep 1998 | A |
5810802 | Panescu et al. | Sep 1998 | A |
5810804 | Gough et al. | Sep 1998 | A |
5823955 | Kuck et al. | Oct 1998 | A |
5827277 | Edwards | Oct 1998 | A |
5830213 | Panescu et al. | Nov 1998 | A |
5833621 | Panescu et al. | Nov 1998 | A |
5833688 | Sieben et al. | Nov 1998 | A |
5836874 | Swanson et al. | Nov 1998 | A |
5836947 | Fleischman et al. | Nov 1998 | A |
5836990 | Li | Nov 1998 | A |
5837001 | Mackey | Nov 1998 | A |
5840076 | Swanson et al. | Nov 1998 | A |
5846238 | Jackson et al. | Dec 1998 | A |
5846239 | Swanson et al. | Dec 1998 | A |
5848969 | Panescu et al. | Dec 1998 | A |
5849028 | Chen | Dec 1998 | A |
5853409 | Swanson et al. | Dec 1998 | A |
5853411 | Whayne et al. | Dec 1998 | A |
5863290 | Gough et al. | Jan 1999 | A |
5865800 | Mirarchi et al. | Feb 1999 | A |
5868736 | Swanson et al. | Feb 1999 | A |
5868743 | Saul et al. | Feb 1999 | A |
5871483 | Jackson et al. | Feb 1999 | A |
5876336 | Swanson et al. | Mar 1999 | A |
5876340 | Tu et al. | Mar 1999 | A |
5879348 | Owens et al. | Mar 1999 | A |
5879349 | Edwards | Mar 1999 | A |
5891136 | McGee et al. | Apr 1999 | A |
5893885 | Webster, Jr. | Apr 1999 | A |
5897552 | Edwards et al. | Apr 1999 | A |
5904651 | Swanson et al. | May 1999 | A |
5904680 | Kordis et al. | May 1999 | A |
5904709 | Arndt et al. | May 1999 | A |
5906590 | Hunjan et al. | May 1999 | A |
5906614 | Stern et al. | May 1999 | A |
5908445 | Whayne et al. | Jun 1999 | A |
5910129 | Koblish et al. | Jun 1999 | A |
5911739 | Kordis et al. | Jun 1999 | A |
5913856 | Chia et al. | Jun 1999 | A |
5916163 | Panescu et al. | Jun 1999 | A |
5919218 | Carr | Jul 1999 | A |
5925038 | Panescu et al. | Jul 1999 | A |
5928228 | Kordis et al. | Jul 1999 | A |
5928229 | Gough et al. | Jul 1999 | A |
5933672 | Huang | Aug 1999 | A |
5935063 | Nguyen | Aug 1999 | A |
5935079 | Swanson et al. | Aug 1999 | A |
5935124 | Klumb et al. | Aug 1999 | A |
5938658 | Tu | Aug 1999 | A |
5938659 | Tu et al. | Aug 1999 | A |
5941251 | Panescu et al. | Aug 1999 | A |
5948009 | Tu | Sep 1999 | A |
5954661 | Greenspon et al. | Sep 1999 | A |
5954662 | Swanson et al. | Sep 1999 | A |
5954719 | Chen et al. | Sep 1999 | A |
5957863 | Koblish et al. | Sep 1999 | A |
5957922 | Imran | Sep 1999 | A |
5957961 | Maguire et al. | Sep 1999 | A |
5961513 | Swanson et al. | Oct 1999 | A |
5964727 | Edwards et al. | Oct 1999 | A |
5967976 | Larsen et al. | Oct 1999 | A |
5968040 | Swanson et al. | Oct 1999 | A |
5971980 | Sherman | Oct 1999 | A |
5974343 | Brevard et al. | Oct 1999 | A |
5980517 | Gough | Nov 1999 | A |
5983124 | Carr | Nov 1999 | A |
5991650 | Swanson et al. | Nov 1999 | A |
5992419 | Sterzer et al. | Nov 1999 | A |
5997534 | Tu et al. | Dec 1999 | A |
6006123 | Nguyen et al. | Dec 1999 | A |
6009351 | Flachman | Dec 1999 | A |
6014581 | Whayne et al. | Jan 2000 | A |
6014590 | Whayne et al. | Jan 2000 | A |
6022346 | Panescu et al. | Feb 2000 | A |
6030379 | Panescu et al. | Feb 2000 | A |
6030382 | Fleischman et al. | Feb 2000 | A |
6032061 | Koblish | Feb 2000 | A |
6035226 | Panescu | Mar 2000 | A |
6047218 | Whayne et al. | Apr 2000 | A |
6048329 | Thompson et al. | Apr 2000 | A |
6049732 | Panescu et al. | Apr 2000 | A |
6053912 | Panescu et al. | Apr 2000 | A |
6056745 | Panescu et al. | May 2000 | A |
6059780 | Gough et al. | May 2000 | A |
6063078 | Wittkampf | May 2000 | A |
6066136 | Geistert | May 2000 | A |
6070094 | Swanson et al. | May 2000 | A |
6071278 | Panescu et al. | Jun 2000 | A |
6076012 | Swanson et al. | Jun 2000 | A |
6080150 | Gough | Jun 2000 | A |
6083222 | Klein et al. | Jul 2000 | A |
6086532 | Panescu et al. | Jul 2000 | A |
6090105 | Zepeda et al. | Jul 2000 | A |
6095150 | Panescu et al. | Aug 2000 | A |
6097976 | Yang et al. | Aug 2000 | A |
6101409 | Swanson et al. | Aug 2000 | A |
6101410 | Panescu et al. | Aug 2000 | A |
6106460 | Panescu et al. | Aug 2000 | A |
6106522 | Fleischman et al. | Aug 2000 | A |
6113591 | Whayne et al. | Sep 2000 | A |
6113593 | Tu et al. | Sep 2000 | A |
6115626 | Whayne et al. | Sep 2000 | A |
6123702 | Swanson et al. | Sep 2000 | A |
6123703 | Tu et al. | Sep 2000 | A |
6129669 | Panescu et al. | Oct 2000 | A |
6129724 | Fleischman et al. | Oct 2000 | A |
6132425 | Gough | Oct 2000 | A |
6142994 | Swanson et al. | Nov 2000 | A |
6146359 | Carr et al. | Nov 2000 | A |
6162184 | Swanson et al. | Dec 2000 | A |
6165169 | Panescu et al. | Dec 2000 | A |
6171275 | Webster, Jr. | Jan 2001 | B1 |
6171306 | Swanson et al. | Jan 2001 | B1 |
6179835 | Panescu et al. | Jan 2001 | B1 |
6183468 | Swanson et al. | Feb 2001 | B1 |
6188924 | Swanson et al. | Feb 2001 | B1 |
6192266 | Dupree et al. | Feb 2001 | B1 |
6193713 | Geistert et al. | Feb 2001 | B1 |
6197021 | Panescu et al. | Mar 2001 | B1 |
6206831 | Suorsa et al. | Mar 2001 | B1 |
6210367 | Carr | Apr 2001 | B1 |
6210406 | Webster | Apr 2001 | B1 |
6216043 | Swanson et al. | Apr 2001 | B1 |
6217528 | Koblish et al. | Apr 2001 | B1 |
6217573 | Webster | Apr 2001 | B1 |
6217574 | Webster | Apr 2001 | B1 |
6217576 | Tu et al. | Apr 2001 | B1 |
6221013 | Panescu et al. | Apr 2001 | B1 |
6230060 | Mawhinney | May 2001 | B1 |
6235022 | Hallock et al. | May 2001 | B1 |
6235023 | Lee et al. | May 2001 | B1 |
6238389 | Paddock et al. | May 2001 | B1 |
6245061 | Panescu et al. | Jun 2001 | B1 |
6245065 | Panescu et al. | Jun 2001 | B1 |
6251107 | Schaer | Jun 2001 | B1 |
6256525 | Yang et al. | Jul 2001 | B1 |
6256540 | Panescu et al. | Jul 2001 | B1 |
6259941 | Chia et al. | Jul 2001 | B1 |
6277113 | Berube | Aug 2001 | B1 |
6283962 | Tu et al. | Sep 2001 | B1 |
6289239 | Panescu et al. | Sep 2001 | B1 |
6293943 | Panescu et al. | Sep 2001 | B1 |
6309385 | Simpson | Oct 2001 | B1 |
6330473 | Swanson et al. | Dec 2001 | B1 |
6346104 | Daly et al. | Feb 2002 | B2 |
6350262 | Ashley | Feb 2002 | B1 |
6352534 | Paddock et al. | Mar 2002 | B1 |
6353751 | Swanson et al. | Mar 2002 | B1 |
6356790 | Maguire et al. | Mar 2002 | B1 |
6357447 | Swanson et al. | Mar 2002 | B1 |
6364876 | Erb et al. | Apr 2002 | B1 |
6370435 | Panescu et al. | Apr 2002 | B2 |
6371955 | Fuimaono et al. | Apr 2002 | B1 |
6389311 | Whayne et al. | May 2002 | B1 |
6391024 | Sun et al. | May 2002 | B1 |
6402739 | Neev | Jun 2002 | B1 |
6402742 | Blewett et al. | Jun 2002 | B1 |
6405067 | Mest et al. | Jun 2002 | B1 |
6423057 | He et al. | Jul 2002 | B1 |
6424869 | Carr et al. | Jul 2002 | B1 |
6425895 | Swanson et al. | Jul 2002 | B1 |
6428536 | Panescu et al. | Aug 2002 | B2 |
6440129 | Simpson | Aug 2002 | B1 |
6445957 | Bolmsjo | Sep 2002 | B1 |
6456864 | Swanson et al. | Sep 2002 | B1 |
6458123 | Brucker et al. | Oct 2002 | B1 |
6463331 | Edwards | Oct 2002 | B1 |
6464700 | Koblish et al. | Oct 2002 | B1 |
6468272 | Koblish et al. | Oct 2002 | B1 |
6470219 | Edwards et al. | Oct 2002 | B1 |
6471699 | Fleischman et al. | Oct 2002 | B1 |
6477396 | Mest et al. | Nov 2002 | B1 |
6477426 | Fenn et al. | Nov 2002 | B1 |
6482203 | Paddock et al. | Nov 2002 | B2 |
6487441 | Swanson et al. | Nov 2002 | B1 |
6488679 | Swanson et al. | Dec 2002 | B1 |
6490488 | Rudie et al. | Dec 2002 | B1 |
6494880 | Swanson et al. | Dec 2002 | B1 |
6496738 | Carr | Dec 2002 | B2 |
6500172 | Panescu et al. | Dec 2002 | B1 |
6500175 | Gough et al. | Dec 2002 | B1 |
6508765 | Suorsa et al. | Jan 2003 | B2 |
6511478 | Burnside et al. | Jan 2003 | B1 |
6514249 | Maguire et al. | Feb 2003 | B1 |
6514250 | Jahns et al. | Feb 2003 | B1 |
6516807 | Panescu et al. | Feb 2003 | B1 |
6522913 | Swanson et al. | Feb 2003 | B2 |
6522930 | Schaer et al. | Feb 2003 | B1 |
6522931 | Manker et al. | Feb 2003 | B2 |
6529756 | Phan et al. | Mar 2003 | B1 |
6537272 | Christopherson et al. | Mar 2003 | B2 |
6542773 | Dupree et al. | Apr 2003 | B2 |
6542781 | Koblish et al. | Apr 2003 | B1 |
6565511 | Panescu et al. | May 2003 | B2 |
6577902 | Laufer et al. | Jun 2003 | B1 |
6579288 | Swanson et al. | Jun 2003 | B1 |
6582425 | Simpson | Jun 2003 | B2 |
6584360 | Francischelli et al. | Jun 2003 | B2 |
6587732 | Carr | Jul 2003 | B1 |
6597955 | Panescu et al. | Jul 2003 | B2 |
6602242 | Fung et al. | Aug 2003 | B1 |
6605087 | Swartz et al. | Aug 2003 | B2 |
6607505 | Thompson et al. | Aug 2003 | B1 |
6610055 | Swanson et al. | Aug 2003 | B1 |
6611699 | Messing | Aug 2003 | B2 |
6613046 | Jenkins et al. | Sep 2003 | B1 |
6615073 | Panescu et al. | Sep 2003 | B1 |
6616657 | Simpson et al. | Sep 2003 | B2 |
6625482 | Panescu et al. | Sep 2003 | B1 |
6632221 | Edwards et al. | Oct 2003 | B1 |
6632222 | Edwards et al. | Oct 2003 | B1 |
6635056 | Kadhiresan et al. | Oct 2003 | B2 |
6645200 | Koblish et al. | Nov 2003 | B1 |
6652513 | Panescu et al. | Nov 2003 | B2 |
6652516 | Gough | Nov 2003 | B1 |
6658279 | Swanson et al. | Dec 2003 | B2 |
6668198 | Swanson et al. | Dec 2003 | B2 |
6669692 | Nelson et al. | Dec 2003 | B1 |
6685702 | Quijano et al. | Feb 2004 | B2 |
6689127 | Gough et al. | Feb 2004 | B1 |
6692490 | Edwards | Feb 2004 | B1 |
6699241 | Rappaport et al. | Mar 2004 | B2 |
6706038 | Francischelli et al. | Mar 2004 | B2 |
6711444 | Koblish | Mar 2004 | B2 |
6735465 | Panescu | May 2004 | B2 |
6736811 | Panescu et al. | May 2004 | B2 |
6740040 | Mandrusov et al. | May 2004 | B1 |
6740083 | Messing | May 2004 | B2 |
6743197 | Edwards | Jun 2004 | B1 |
6743225 | Sanchez et al. | Jun 2004 | B2 |
6745080 | Koblish | Jun 2004 | B2 |
6746401 | Panescu | Jun 2004 | B2 |
6752804 | Simpson et al. | Jun 2004 | B2 |
6752805 | Maguire et al. | Jun 2004 | B2 |
6770070 | Balbierz | Aug 2004 | B1 |
6773433 | Stewart et al. | Aug 2004 | B2 |
6786905 | Swanson et al. | Sep 2004 | B2 |
6788969 | Dupree et al. | Sep 2004 | B2 |
6788977 | Fenn et al. | Sep 2004 | B2 |
6790206 | Panescu | Sep 2004 | B2 |
6805129 | Pless et al. | Oct 2004 | B1 |
6814730 | Li | Nov 2004 | B2 |
6823216 | Salomir et al. | Nov 2004 | B1 |
6824515 | Suorsa et al. | Nov 2004 | B2 |
6827715 | Francischelli et al. | Dec 2004 | B2 |
6837885 | Koblish et al. | Jan 2005 | B2 |
6840936 | Sliwa, Jr. et al. | Jan 2005 | B2 |
6847848 | Sterzer et al. | Jan 2005 | B2 |
6849073 | Hoey et al. | Feb 2005 | B2 |
6852120 | Fuimaono | Feb 2005 | B1 |
6887238 | Jahns et al. | May 2005 | B2 |
6888141 | Carr | May 2005 | B2 |
6895267 | Panescu et al. | May 2005 | B2 |
6904303 | Phan et al. | Jun 2005 | B2 |
6905495 | Fuimaono et al. | Jun 2005 | B1 |
6917834 | Koblish et al. | Jul 2005 | B2 |
6932776 | Carr | Aug 2005 | B2 |
6932813 | Thompson et al. | Aug 2005 | B2 |
6936047 | Nasab et al. | Aug 2005 | B2 |
6942661 | Swanson | Sep 2005 | B2 |
6949095 | Vaska et al. | Sep 2005 | B2 |
6953460 | Maguire et al. | Oct 2005 | B2 |
6958075 | Mon et al. | Oct 2005 | B2 |
6960205 | Jahns et al. | Nov 2005 | B2 |
6960207 | Vanney et al. | Nov 2005 | B2 |
6974455 | Garabedian et al. | Dec 2005 | B2 |
6976492 | Ingle et al. | Dec 2005 | B2 |
6979329 | Burnside et al. | Dec 2005 | B2 |
6984232 | Vanney et al. | Jan 2006 | B2 |
6986769 | Nelson et al. | Jan 2006 | B2 |
7001383 | Keidar | Feb 2006 | B2 |
7008417 | Eick | Mar 2006 | B2 |
7029470 | Francischelli et al. | Apr 2006 | B2 |
7052492 | Swanson et al. | May 2006 | B2 |
7101387 | Garabedian et al. | Sep 2006 | B2 |
7150744 | Edwards et al. | Dec 2006 | B2 |
7151964 | Desai et al. | Dec 2006 | B2 |
7160296 | Pearson et al. | Jan 2007 | B2 |
7163537 | Lee et al. | Jan 2007 | B2 |
7166075 | Varghese et al. | Jan 2007 | B2 |
7175619 | Koblish et al. | Feb 2007 | B2 |
7175734 | Stewart et al. | Feb 2007 | B2 |
7184811 | Phan et al. | Feb 2007 | B2 |
7186250 | Koblish et al. | Mar 2007 | B2 |
7194294 | Panescu et al. | Mar 2007 | B2 |
7197356 | Carr | Mar 2007 | B2 |
7229437 | Johnson et al. | Jun 2007 | B2 |
7238184 | Megerman et al. | Jul 2007 | B2 |
7252664 | Nasab et al. | Aug 2007 | B2 |
7263398 | Carr | Aug 2007 | B2 |
7276061 | Schaer et al. | Oct 2007 | B2 |
7285116 | de la Rama et al. | Oct 2007 | B2 |
7303558 | Swanson | Dec 2007 | B2 |
7306593 | Keidar et al. | Dec 2007 | B2 |
7326208 | Vanney et al. | Feb 2008 | B2 |
7326235 | Edwards | Feb 2008 | B2 |
7331960 | Schaer | Feb 2008 | B2 |
7338486 | Sliwa et al. | Mar 2008 | B2 |
7344533 | Pearson et al. | Mar 2008 | B2 |
7364546 | Panescu et al. | Apr 2008 | B2 |
7364578 | Francischelli et al. | Apr 2008 | B2 |
7367972 | Francischelli et al. | May 2008 | B2 |
7371233 | Swanson et al. | May 2008 | B2 |
7371235 | Thompson et al. | May 2008 | B2 |
7435248 | Taimisto et al. | Oct 2008 | B2 |
7474909 | Phan et al. | Jan 2009 | B2 |
7565208 | Harris et al. | Jul 2009 | B2 |
7582050 | Schlorff et al. | Sep 2009 | B2 |
7582084 | Swanson et al. | Sep 2009 | B2 |
7588568 | Fuimaono et al. | Sep 2009 | B2 |
7588658 | Yamamoto et al. | Sep 2009 | B2 |
7623899 | Worley et al. | Nov 2009 | B2 |
7628788 | Datta | Dec 2009 | B2 |
7662152 | Sharareh et al. | Feb 2010 | B2 |
7669309 | Johnson et al. | Mar 2010 | B2 |
7670336 | Young et al. | Mar 2010 | B2 |
7676264 | Pillai et al. | Mar 2010 | B1 |
7678104 | Keidar | Mar 2010 | B2 |
7699829 | Harris et al. | Apr 2010 | B2 |
7699841 | Carr | Apr 2010 | B2 |
7715926 | Boser et al. | May 2010 | B2 |
7727230 | Fuimaono et al. | Jun 2010 | B2 |
7734330 | Carr | Jun 2010 | B2 |
7761148 | Fuimaono et al. | Jul 2010 | B2 |
7764994 | Fuimaono et al. | Jul 2010 | B2 |
7766693 | Sartor et al. | Aug 2010 | B2 |
7766907 | Dando et al. | Aug 2010 | B2 |
7769469 | Carr et al. | Aug 2010 | B2 |
7771418 | Chopra et al. | Aug 2010 | B2 |
7771420 | Butty et al. | Aug 2010 | B2 |
7774039 | Koblish | Aug 2010 | B2 |
7776034 | Kampa | Aug 2010 | B2 |
7794404 | Gutfinger et al. | Sep 2010 | B1 |
7794460 | Mulier et al. | Sep 2010 | B2 |
7811313 | Mon et al. | Oct 2010 | B2 |
7815635 | Wittkampf et al. | Oct 2010 | B2 |
7819862 | Pachon Mateos et al. | Oct 2010 | B2 |
7819866 | Bednarek | Oct 2010 | B2 |
7824399 | Francischelli et al. | Nov 2010 | B2 |
7826904 | Appling et al. | Nov 2010 | B2 |
7833220 | Mon et al. | Nov 2010 | B2 |
7837720 | Mon | Nov 2010 | B2 |
7857809 | Drysen | Dec 2010 | B2 |
7857810 | Wang et al. | Dec 2010 | B2 |
7862563 | Cosman et al. | Jan 2011 | B1 |
7867227 | Slater | Jan 2011 | B2 |
7879029 | Jimenez | Feb 2011 | B2 |
7914528 | Wang et al. | Mar 2011 | B2 |
7918850 | Govari et al. | Apr 2011 | B2 |
7918851 | Webster, Jr. et al. | Apr 2011 | B2 |
7925341 | Fuimaono | Apr 2011 | B2 |
7925349 | Wong et al. | Apr 2011 | B1 |
7927328 | Orszulak et al. | Apr 2011 | B2 |
7933660 | Carr | Apr 2011 | B2 |
7938828 | Koblish | May 2011 | B2 |
7945326 | Wong et al. | May 2011 | B1 |
7946995 | Koh et al. | May 2011 | B1 |
7955369 | Thompson et al. | Jun 2011 | B2 |
7957813 | Persson | Jun 2011 | B1 |
7959628 | Schaer et al. | Jun 2011 | B2 |
7959630 | Taimisto et al. | Jun 2011 | B2 |
7963925 | Schecter | Jun 2011 | B1 |
7967817 | Anderson et al. | Jun 2011 | B2 |
7976537 | Lieber et al. | Jul 2011 | B2 |
7989741 | Carr | Aug 2011 | B2 |
7996078 | Paul et al. | Aug 2011 | B2 |
7998140 | McClurken et al. | Aug 2011 | B2 |
7998141 | Wttkampf et al. | Aug 2011 | B2 |
8002770 | Swanson et al. | Aug 2011 | B2 |
8007497 | Young et al. | Aug 2011 | B2 |
8010196 | Wong et al. | Aug 2011 | B1 |
8011055 | Lesley | Sep 2011 | B2 |
8012150 | Wham et al. | Sep 2011 | B2 |
8019419 | Panescu et al. | Sep 2011 | B1 |
8032218 | Wong et al. | Oct 2011 | B2 |
8034050 | Sharareh et al. | Oct 2011 | B2 |
8034052 | Podhajsky | Oct 2011 | B2 |
8038670 | McClurken | Oct 2011 | B2 |
8048070 | O'Brien et al. | Nov 2011 | B2 |
8052680 | Hassett et al. | Nov 2011 | B2 |
8052684 | Wang et al. | Nov 2011 | B2 |
8062228 | Carr | Nov 2011 | B2 |
8065005 | Wong et al. | Nov 2011 | B1 |
8083736 | McClurken et al. | Dec 2011 | B2 |
8100895 | Panos et al. | Jan 2012 | B2 |
8104956 | Blaha | Jan 2012 | B2 |
8118809 | Paul et al. | Feb 2012 | B2 |
8123745 | Beeckler et al. | Feb 2012 | B2 |
8128617 | Bencini et al. | Mar 2012 | B2 |
8128621 | Wang et al. | Mar 2012 | B2 |
8133220 | Lee et al. | Mar 2012 | B2 |
8145289 | Calabro′ et al. | Mar 2012 | B2 |
8152801 | Goldberg et al. | Apr 2012 | B2 |
8157796 | Collins et al. | Apr 2012 | B2 |
8160693 | Fuimaono | Apr 2012 | B2 |
8175680 | Panescu | May 2012 | B2 |
8192424 | Woloszko | Jun 2012 | B2 |
8202224 | Gutfinger et al. | Jun 2012 | B2 |
8206380 | Lenihan et al. | Jun 2012 | B2 |
8206383 | Hauck et al. | Jun 2012 | B2 |
8206385 | Stangenes et al. | Jun 2012 | B2 |
8208999 | Wenzel et al. | Jun 2012 | B2 |
8211099 | Buysse et al. | Jul 2012 | B2 |
8216216 | Warnking et al. | Jul 2012 | B2 |
8221408 | Johnson et al. | Jul 2012 | B2 |
8221413 | Mon et al. | Jul 2012 | B2 |
8221414 | Mon et al. | Jul 2012 | B2 |
8224455 | Mon et al. | Jul 2012 | B2 |
8226645 | Harrington et al. | Jul 2012 | B2 |
8229538 | Koblish | Jul 2012 | B2 |
8256428 | Hindricks et al. | Sep 2012 | B2 |
8262652 | Podhajsky | Sep 2012 | B2 |
8262653 | Plaza | Sep 2012 | B2 |
8265747 | Rittman, III et al. | Sep 2012 | B2 |
8267926 | Paul et al. | Sep 2012 | B2 |
8267929 | Wham et al. | Sep 2012 | B2 |
8267932 | Baxter et al. | Sep 2012 | B2 |
8273082 | Wang et al. | Sep 2012 | B2 |
8280511 | Zhao et al. | Oct 2012 | B2 |
8287532 | Carroll et al. | Oct 2012 | B2 |
8287533 | Wittkampf | Oct 2012 | B2 |
8290578 | Schneider | Oct 2012 | B2 |
8298223 | Wham et al. | Oct 2012 | B2 |
8298227 | Leo et al. | Oct 2012 | B2 |
8303172 | Zei et al. | Nov 2012 | B2 |
8303580 | Wham et al. | Nov 2012 | B2 |
8306623 | Wong et al. | Nov 2012 | B2 |
8308719 | Sliwa et al. | Nov 2012 | B2 |
8317783 | Cao et al. | Nov 2012 | B2 |
8321019 | Esch et al. | Nov 2012 | B2 |
8333759 | Podhajsky | Dec 2012 | B2 |
8333762 | Mest et al. | Dec 2012 | B2 |
8348937 | Wang et al. | Jan 2013 | B2 |
8359092 | Hayam et al. | Jan 2013 | B2 |
8369922 | Paul et al. | Feb 2013 | B2 |
8372066 | Manwaring et al. | Feb 2013 | B2 |
8374670 | Selkee | Feb 2013 | B2 |
8374702 | Mon et al. | Feb 2013 | B2 |
8377052 | Manwaring et al. | Feb 2013 | B2 |
8377054 | Gilbert | Feb 2013 | B2 |
8380275 | Kim et al. | Feb 2013 | B2 |
8386049 | Persson et al. | Feb 2013 | B2 |
8394093 | Wang et al. | Mar 2013 | B2 |
8398623 | Warnking et al. | Mar 2013 | B2 |
8403925 | Miller et al. | Mar 2013 | B2 |
8406866 | Deno et al. | Mar 2013 | B2 |
8409191 | Avitall et al. | Apr 2013 | B2 |
8409192 | Asirvatham et al. | Apr 2013 | B2 |
8414570 | Turner et al. | Apr 2013 | B2 |
8414579 | Kim et al. | Apr 2013 | B2 |
8419725 | Haemmerich et al. | Apr 2013 | B2 |
8423115 | Koblish | Apr 2013 | B2 |
8440949 | Carr | May 2013 | B2 |
8442613 | Kim et al. | May 2013 | B2 |
8444637 | Podmore et al. | May 2013 | B2 |
8449535 | Deno et al. | May 2013 | B2 |
8449537 | Cao et al. | May 2013 | B2 |
8449539 | Wang et al. | May 2013 | B2 |
8460285 | Wang et al. | Jun 2013 | B2 |
8473023 | Worley et al. | Jun 2013 | B2 |
8475448 | Sharareh et al. | Jul 2013 | B2 |
8475450 | Govari et al. | Jul 2013 | B2 |
8480663 | Ingle et al. | Jul 2013 | B2 |
8480666 | Buysse et al. | Jul 2013 | B2 |
8486065 | Lee et al. | Jul 2013 | B2 |
8491578 | Manwaring et al. | Jul 2013 | B2 |
8504152 | Wenzel et al. | Aug 2013 | B2 |
8504153 | Wenzel et al. | Aug 2013 | B2 |
8515554 | Carr | Aug 2013 | B2 |
8517999 | Pappone et al. | Aug 2013 | B2 |
8523851 | Manwaring et al. | Sep 2013 | B2 |
8523852 | Manwaring et al. | Sep 2013 | B2 |
8535303 | Avitall et al. | Sep 2013 | B2 |
8545409 | Sliwa et al. | Oct 2013 | B2 |
8554333 | Wu et al. | Oct 2013 | B2 |
8556893 | Potter | Oct 2013 | B2 |
8560086 | Just et al. | Oct 2013 | B2 |
8562600 | Kirkpatrick et al. | Oct 2013 | B2 |
8568402 | Buysse et al. | Oct 2013 | B2 |
8574166 | Carr | Nov 2013 | B2 |
8600472 | Govari et al. | Dec 2013 | B2 |
8600497 | Yang et al. | Dec 2013 | B1 |
8603084 | Fish et al. | Dec 2013 | B2 |
8603085 | Jimenez | Dec 2013 | B2 |
8628520 | Sharareh et al. | Jan 2014 | B2 |
8632533 | Greeley et al. | Jan 2014 | B2 |
8636729 | Esch et al. | Jan 2014 | B2 |
8641708 | Govari et al. | Feb 2014 | B2 |
8657814 | Werneth et al. | Feb 2014 | B2 |
8663122 | Schecter | Mar 2014 | B2 |
8668686 | Govari et al. | Mar 2014 | B2 |
8679109 | Paul et al. | Mar 2014 | B2 |
8690870 | Wang et al. | Apr 2014 | B2 |
8696659 | Marion | Apr 2014 | B2 |
8700120 | Koblish | Apr 2014 | B2 |
8702690 | Paul et al. | Apr 2014 | B2 |
8702693 | Subramaniam et al. | Apr 2014 | B2 |
8712519 | Panescu et al. | Apr 2014 | B1 |
8721634 | Esch et al. | May 2014 | B2 |
8721636 | Vaska et al. | May 2014 | B2 |
8725228 | Koblish et al. | May 2014 | B2 |
8728074 | West et al. | May 2014 | B2 |
8728077 | Paul et al. | May 2014 | B2 |
8731631 | Kim et al. | May 2014 | B2 |
8731684 | Carr et al. | May 2014 | B2 |
8734442 | Cao et al. | May 2014 | B2 |
8740900 | Kim et al. | Jun 2014 | B2 |
8755860 | Paul et al. | Jun 2014 | B2 |
8764746 | Podmore et al. | Jul 2014 | B2 |
8777942 | Wu et al. | Jul 2014 | B2 |
8784414 | Avitall et al. | Jul 2014 | B2 |
8792958 | Kim et al. | Jul 2014 | B2 |
8795271 | Koblish et al. | Aug 2014 | B2 |
8798706 | Kim et al. | Aug 2014 | B2 |
8814824 | Kauphusman et al. | Aug 2014 | B2 |
8814857 | Christian | Aug 2014 | B2 |
8834388 | Sherman | Sep 2014 | B2 |
8834461 | Werneth et al. | Sep 2014 | B2 |
8845629 | Demarais et al. | Sep 2014 | B2 |
8845631 | Werneth et al. | Sep 2014 | B2 |
8845633 | Wang et al. | Sep 2014 | B2 |
8858548 | Asconeguy | Oct 2014 | B2 |
8868165 | Nabutovsky et al. | Oct 2014 | B1 |
8876817 | Avitall et al. | Nov 2014 | B2 |
8876819 | Tegg et al. | Nov 2014 | B2 |
8882755 | Leung et al. | Nov 2014 | B2 |
8882759 | Manley et al. | Nov 2014 | B2 |
8882761 | Desai | Nov 2014 | B2 |
8894642 | Gibson et al. | Nov 2014 | B2 |
8900225 | Bar-Tai et al. | Dec 2014 | B2 |
8900228 | Grunewald et al. | Dec 2014 | B2 |
8906010 | Edwards et al. | Dec 2014 | B2 |
8920415 | Govari | Dec 2014 | B2 |
8926605 | McCarthy et al. | Jan 2015 | B2 |
8932284 | McCarthy et al. | Jan 2015 | B2 |
8934953 | Carr et al. | Jan 2015 | B2 |
8942828 | Schecter | Jan 2015 | B1 |
8945015 | Rankin et al. | Feb 2015 | B2 |
8945117 | Bencini | Feb 2015 | B2 |
8954161 | McCarthy et al. | Feb 2015 | B2 |
8956304 | Schecter | Feb 2015 | B2 |
8961506 | McCarthy et al. | Feb 2015 | B2 |
8968299 | Kauphusman et al. | Mar 2015 | B2 |
8974454 | de la Rama et al. | Mar 2015 | B2 |
8992519 | Kim et al. | Mar 2015 | B2 |
8998890 | Paul et al. | Apr 2015 | B2 |
9014814 | McCarthy et al. | Apr 2015 | B2 |
9023030 | Koblish et al. | May 2015 | B2 |
9050069 | Lalonde et al. | Jun 2015 | B2 |
9060756 | Bencini et al. | Jun 2015 | B2 |
9066662 | Wenzel et al. | Jun 2015 | B2 |
9066725 | Christian | Jun 2015 | B2 |
9089339 | McDaniel | Jul 2015 | B2 |
9089340 | Hastings et al. | Jul 2015 | B2 |
9095349 | Fish et al. | Aug 2015 | B2 |
9144460 | Clark et al. | Sep 2015 | B2 |
9173586 | Deno et al. | Nov 2015 | B2 |
9179972 | Olson | Nov 2015 | B2 |
9204927 | Afonso et al. | Dec 2015 | B2 |
9226791 | McCarthy et al. | Jan 2016 | B2 |
9226793 | Jimenez | Jan 2016 | B2 |
9254163 | Paul et al. | Feb 2016 | B2 |
9265574 | Bar-Tai et al. | Feb 2016 | B2 |
9271782 | Paul et al. | Mar 2016 | B2 |
9277961 | Panescu et al. | Mar 2016 | B2 |
9283025 | Paul et al. | Mar 2016 | B2 |
9283026 | Paul et al. | Mar 2016 | B2 |
9364282 | Just et al. | Jun 2016 | B2 |
9364286 | Werneth et al. | Jun 2016 | B2 |
9370311 | Stewart et al. | Jun 2016 | B2 |
9456867 | Lawrence et al. | Oct 2016 | B2 |
9474458 | Clark et al. | Oct 2016 | B2 |
9510893 | Jimenez | Dec 2016 | B2 |
9510894 | Clark et al. | Dec 2016 | B2 |
9510905 | Panescu et al. | Dec 2016 | B2 |
9517103 | Panescu et al. | Dec 2016 | B2 |
9522036 | Panescu et al. | Dec 2016 | B2 |
9522037 | Panescu et al. | Dec 2016 | B2 |
9592092 | Panescu et al. | Mar 2017 | B2 |
9636164 | Panescu et al. | May 2017 | B2 |
20010001830 | Dobak et al. | May 2001 | A1 |
20010007927 | Koblish et al. | Jul 2001 | A1 |
20020004631 | Jenkins et al. | Jan 2002 | A1 |
20020022829 | Nagase et al. | Feb 2002 | A1 |
20020026185 | Gough | Feb 2002 | A1 |
20020040229 | Norman | Apr 2002 | A1 |
20020058870 | Panescu et al. | May 2002 | A1 |
20020065465 | Panescu et al. | May 2002 | A1 |
20020115941 | Whayne et al. | Aug 2002 | A1 |
20020128636 | Chin et al. | Sep 2002 | A1 |
20020128639 | Pless et al. | Sep 2002 | A1 |
20020128643 | Simpson et al. | Sep 2002 | A1 |
20020165529 | Danek | Nov 2002 | A1 |
20020169444 | Mest et al. | Nov 2002 | A1 |
20020183736 | Francischelli et al. | Dec 2002 | A1 |
20020193790 | Fleischman et al. | Dec 2002 | A1 |
20020198520 | Coen et al. | Dec 2002 | A1 |
20030014049 | Koblish et al. | Jan 2003 | A1 |
20030050557 | Susil et al. | Mar 2003 | A1 |
20030055470 | Mon et al. | Mar 2003 | A1 |
20030065322 | Panescu et al. | Apr 2003 | A1 |
20030069619 | Fenn et al. | Apr 2003 | A1 |
20030078509 | Panescu | Apr 2003 | A1 |
20030078573 | Truckai et al. | Apr 2003 | A1 |
20030088244 | Swanson et al. | May 2003 | A1 |
20030093067 | Panescu | May 2003 | A1 |
20030120171 | Diamantopoulos et al. | Jun 2003 | A1 |
20030153967 | Koblish et al. | Aug 2003 | A1 |
20030195406 | Jenkins et al. | Oct 2003 | A1 |
20030199817 | Thompson et al. | Oct 2003 | A1 |
20040044340 | Francischelli et al. | Mar 2004 | A1 |
20040054272 | Messing | Mar 2004 | A1 |
20040092806 | Sagon et al. | May 2004 | A1 |
20040097803 | Panescu | May 2004 | A1 |
20040138656 | Francischelli et al. | Jul 2004 | A1 |
20040147915 | Hasebe | Jul 2004 | A1 |
20040260278 | Anderson et al. | Dec 2004 | A1 |
20050015082 | O'Sullivan et al. | Jan 2005 | A1 |
20050033221 | Fiumaono | Feb 2005 | A1 |
20050059963 | Phan et al. | Mar 2005 | A1 |
20050143727 | Koblish et al. | Jun 2005 | A1 |
20050177151 | Coen et al. | Aug 2005 | A1 |
20050197657 | Goth et al. | Sep 2005 | A1 |
20050228370 | Sterzer et al. | Oct 2005 | A1 |
20050245949 | Goth et al. | Nov 2005 | A1 |
20050251125 | Pless et al. | Nov 2005 | A1 |
20060025758 | Strul et al. | Feb 2006 | A1 |
20060064083 | Khalaj et al. | Mar 2006 | A1 |
20060089688 | Panescu | Apr 2006 | A1 |
20060095032 | Jackson et al. | May 2006 | A1 |
20060135957 | Panescu | Jun 2006 | A1 |
20060167445 | Shafirstein | Jul 2006 | A1 |
20060184166 | Valle et al. | Aug 2006 | A1 |
20060184221 | Stewart et al. | Aug 2006 | A1 |
20060217701 | Young et al. | Sep 2006 | A1 |
20060247615 | McCullagh et al. | Nov 2006 | A1 |
20060253115 | Avitall et al. | Nov 2006 | A1 |
20060293731 | Rubinsky et al. | Dec 2006 | A1 |
20070032788 | Edwards et al. | Feb 2007 | A1 |
20070049925 | Phan et al. | Mar 2007 | A1 |
20070055227 | Khalaj et al. | Mar 2007 | A1 |
20070055326 | Farley et al. | Mar 2007 | A1 |
20070055328 | Mayse et al. | Mar 2007 | A1 |
20070066968 | Rahn | Mar 2007 | A1 |
20070066972 | Ormsby et al. | Mar 2007 | A1 |
20070073286 | Panescu et al. | Mar 2007 | A1 |
20070129720 | Demarais et al. | Jun 2007 | A1 |
20070135810 | Lee et al. | Jun 2007 | A1 |
20070149963 | Matsukuma et al. | Jun 2007 | A1 |
20070156048 | Panescu et al. | Jul 2007 | A1 |
20070156114 | Worley et al. | Jul 2007 | A1 |
20070179378 | Boese et al. | Aug 2007 | A1 |
20070185478 | Cosentino | Aug 2007 | A1 |
20070198007 | Govari et al. | Aug 2007 | A1 |
20070225697 | Shroff et al. | Sep 2007 | A1 |
20070244476 | Kochamba et al. | Oct 2007 | A1 |
20070244534 | Kochamba et al. | Oct 2007 | A1 |
20070299488 | Carr | Dec 2007 | A1 |
20080015563 | Hoey et al. | Jan 2008 | A1 |
20080015571 | Rubinsky et al. | Jan 2008 | A1 |
20080033300 | Hoang et al. | Feb 2008 | A1 |
20080077126 | Rashidi | Mar 2008 | A1 |
20080082091 | Rubtsov et al. | Apr 2008 | A1 |
20080161791 | Cao et al. | Jul 2008 | A1 |
20080161797 | Wang et al. | Jul 2008 | A1 |
20080172048 | Martin et al. | Jul 2008 | A1 |
20080177205 | Rama et al. | Jul 2008 | A1 |
20080243112 | De Neve | Oct 2008 | A1 |
20080243214 | Koblish | Oct 2008 | A1 |
20080249463 | Pappone et al. | Oct 2008 | A1 |
20080275440 | Kratoska et al. | Nov 2008 | A1 |
20080300589 | Paul et al. | Dec 2008 | A1 |
20080312521 | Solomon | Dec 2008 | A1 |
20090005768 | Sharareh et al. | Jan 2009 | A1 |
20090036882 | Webster et al. | Feb 2009 | A1 |
20090069808 | Pike, Jr. et al. | Mar 2009 | A1 |
20090076409 | Wu et al. | Mar 2009 | A1 |
20090093810 | Subramaniam et al. | Apr 2009 | A1 |
20090099560 | Rioux et al. | Apr 2009 | A1 |
20090118613 | Krugman et al. | May 2009 | A1 |
20090163916 | Paul et al. | Jun 2009 | A1 |
20090177111 | Miller et al. | Jul 2009 | A1 |
20090177193 | Wang et al. | Jul 2009 | A1 |
20090187183 | Epstein | Jul 2009 | A1 |
20090221999 | Shahidi | Sep 2009 | A1 |
20090248006 | Paulus et al. | Oct 2009 | A1 |
20090254083 | Wallace et al. | Oct 2009 | A1 |
20090275827 | Aiken et al. | Nov 2009 | A1 |
20090287201 | Lalonde et al. | Nov 2009 | A1 |
20090306641 | Govari et al. | Dec 2009 | A1 |
20090306643 | Pappone et al. | Dec 2009 | A1 |
20090312754 | Lenihan et al. | Dec 2009 | A1 |
20090312756 | Schlesinger et al. | Dec 2009 | A1 |
20100016848 | Desai | Jan 2010 | A1 |
20100023000 | Stevenson | Jan 2010 | A1 |
20100030209 | Govari et al. | Feb 2010 | A1 |
20100049011 | Boese et al. | Feb 2010 | A1 |
20100057072 | Roman et al. | Mar 2010 | A1 |
20100057073 | Roman et al. | Mar 2010 | A1 |
20100057074 | Roman et al. | Mar 2010 | A1 |
20100057080 | West et al. | Mar 2010 | A1 |
20100076424 | Carr | Mar 2010 | A1 |
20100094271 | Ward et al. | Apr 2010 | A1 |
20100114087 | Edwards et al. | May 2010 | A1 |
20100114227 | Cholette | May 2010 | A1 |
20100137837 | Govari et al. | Jun 2010 | A1 |
20100137857 | Shroff et al. | Jun 2010 | A1 |
20100152724 | Marion et al. | Jun 2010 | A1 |
20100168570 | Sliwa et al. | Jul 2010 | A1 |
20100168571 | Savery et al. | Jul 2010 | A1 |
20100168620 | Klimovitch et al. | Jul 2010 | A1 |
20100174280 | Grimaldi | Jul 2010 | A1 |
20100185191 | Carr et al. | Jul 2010 | A1 |
20100198312 | Stevenson et al. | Aug 2010 | A1 |
20100204691 | Bencini | Aug 2010 | A1 |
20100211070 | Subramaniam et al. | Aug 2010 | A1 |
20100217255 | Greeley et al. | Aug 2010 | A1 |
20100222859 | Govari et al. | Sep 2010 | A1 |
20100286684 | Hata et al. | Nov 2010 | A1 |
20100286690 | Paul et al. | Nov 2010 | A1 |
20100298823 | Cao et al. | Nov 2010 | A1 |
20100331838 | Ibrahim et al. | Dec 2010 | A1 |
20110009857 | Subramaniam et al. | Jan 2011 | A1 |
20110022041 | Ingle et al. | Jan 2011 | A1 |
20110028821 | Bojovic et al. | Feb 2011 | A1 |
20110066147 | He et al. | Mar 2011 | A1 |
20110077498 | McDaniel | Mar 2011 | A1 |
20110105928 | Bojovic et al. | May 2011 | A1 |
20110112413 | Panescu et al. | May 2011 | A1 |
20110112414 | Panescu | May 2011 | A1 |
20110112415 | Bojovic et al. | May 2011 | A1 |
20110118726 | de la Rama et al. | May 2011 | A1 |
20110144479 | Hastings et al. | Jun 2011 | A1 |
20110144524 | Fish et al. | Jun 2011 | A1 |
20110144639 | Govari | Jun 2011 | A1 |
20110152853 | Manley et al. | Jun 2011 | A1 |
20110160726 | Ingle | Jun 2011 | A1 |
20110166472 | Björling et al. | Jul 2011 | A1 |
20110172658 | Gelbart et al. | Jul 2011 | A1 |
20110184300 | Shvilkin et al. | Jul 2011 | A1 |
20110184313 | Gianchandani et al. | Jul 2011 | A1 |
20110213356 | Wright et al. | Sep 2011 | A1 |
20110224573 | Bar-Tal et al. | Sep 2011 | A1 |
20110224664 | Bar-Tal et al. | Sep 2011 | A1 |
20110224667 | Koblish et al. | Sep 2011 | A1 |
20110257645 | Thompson et al. | Oct 2011 | A1 |
20110264000 | Paul et al. | Oct 2011 | A1 |
20110264011 | Wu et al. | Oct 2011 | A1 |
20110264089 | Zirkle et al. | Oct 2011 | A1 |
20110270244 | Clark et al. | Nov 2011 | A1 |
20110270246 | Clark et al. | Nov 2011 | A1 |
20110282250 | Fung et al. | Nov 2011 | A1 |
20110282342 | Leo et al. | Nov 2011 | A1 |
20110288544 | Verin et al. | Nov 2011 | A1 |
20110295247 | Schlesinger et al. | Dec 2011 | A1 |
20110319748 | Bronskill et al. | Dec 2011 | A1 |
20120029504 | Afonso et al. | Feb 2012 | A1 |
20120029511 | Smith et al. | Feb 2012 | A1 |
20120029512 | Willard et al. | Feb 2012 | A1 |
20120035603 | Lenihan | Feb 2012 | A1 |
20120059368 | Takaoka et al. | Mar 2012 | A1 |
20120071870 | Salahieh | Mar 2012 | A1 |
20120078138 | Leo et al. | Mar 2012 | A1 |
20120089123 | Organ et al. | Apr 2012 | A1 |
20120101538 | Ballakur et al. | Apr 2012 | A1 |
20120116392 | Willard | May 2012 | A1 |
20120123411 | Ibrahim et al. | May 2012 | A1 |
20120130364 | Besch et al. | May 2012 | A1 |
20120136346 | Condie et al. | May 2012 | A1 |
20120143097 | Pike, Jr. | Jun 2012 | A1 |
20120150170 | Buysse et al. | Jun 2012 | A1 |
20120157890 | Govari et al. | Jun 2012 | A1 |
20120157990 | Christian | Jun 2012 | A1 |
20120165809 | Christian et al. | Jun 2012 | A1 |
20120172859 | Condie et al. | Jul 2012 | A1 |
20120179068 | Leo et al. | Jul 2012 | A1 |
20120189998 | Kruecker et al. | Jul 2012 | A1 |
20120197243 | Sherman et al. | Aug 2012 | A1 |
20120239019 | Asconeguy | Sep 2012 | A1 |
20120245577 | Mihalik et al. | Sep 2012 | A1 |
20120253340 | Stevenson et al. | Oct 2012 | A1 |
20120265076 | Schecter | Oct 2012 | A1 |
20120265137 | Mon | Oct 2012 | A1 |
20120265190 | Curley et al. | Oct 2012 | A1 |
20120271306 | Buysse et al. | Oct 2012 | A1 |
20120277574 | Panescu | Nov 2012 | A1 |
20120277737 | Curley | Nov 2012 | A1 |
20120283534 | Carr et al. | Nov 2012 | A1 |
20120283722 | Asconeguy | Nov 2012 | A1 |
20120302877 | Harks et al. | Nov 2012 | A1 |
20120303103 | Mon et al. | Nov 2012 | A1 |
20130006139 | Tiano | Jan 2013 | A1 |
20130006238 | Ditter et al. | Jan 2013 | A1 |
20130030385 | Schultz et al. | Jan 2013 | A1 |
20130030426 | Gallardo et al. | Jan 2013 | A1 |
20130030427 | Betts et al. | Jan 2013 | A1 |
20130060245 | Grunewald et al. | Mar 2013 | A1 |
20130066312 | Subramaniam et al. | Mar 2013 | A1 |
20130066315 | Subramaniam et al. | Mar 2013 | A1 |
20130079768 | De Luca et al. | Mar 2013 | A1 |
20130096447 | Dhawan et al. | Apr 2013 | A1 |
20130110104 | Corvi et al. | May 2013 | A1 |
20130123775 | Grunewald et al. | May 2013 | A1 |
20130137999 | Wenzel et al. | May 2013 | A1 |
20130158536 | Bloom | Jun 2013 | A1 |
20130172742 | Rankin et al. | Jul 2013 | A1 |
20130172873 | Govari et al. | Jul 2013 | A1 |
20130172879 | Sutermeister et al. | Jul 2013 | A1 |
20130184549 | Avitall et al. | Jul 2013 | A1 |
20130190747 | Koblish et al. | Jul 2013 | A1 |
20130197504 | Cronin et al. | Aug 2013 | A1 |
20130197507 | Kim et al. | Aug 2013 | A1 |
20130204124 | Duindam et al. | Aug 2013 | A1 |
20130204240 | McCarthy et al. | Aug 2013 | A1 |
20130226169 | Miller et al. | Aug 2013 | A1 |
20130237977 | McCarthy et al. | Sep 2013 | A1 |
20130237979 | Shikhman et al. | Sep 2013 | A1 |
20130253504 | Fang | Sep 2013 | A1 |
20130253505 | Schultz | Sep 2013 | A1 |
20130272339 | Tofighi | Oct 2013 | A1 |
20130281851 | Carr et al. | Oct 2013 | A1 |
20130289550 | Ingle et al. | Oct 2013 | A1 |
20130303892 | Zhao et al. | Nov 2013 | A1 |
20130303945 | Blumenkranz et al. | Nov 2013 | A1 |
20130310674 | Deno et al. | Nov 2013 | A1 |
20130324993 | McCarthy et al. | Dec 2013 | A1 |
20130338664 | Wang et al. | Dec 2013 | A1 |
20130345692 | Brannan | Dec 2013 | A1 |
20140012132 | Carr et al. | Jan 2014 | A1 |
20140018697 | Allison | Jan 2014 | A1 |
20140018793 | Sharonov | Jan 2014 | A1 |
20140025056 | Dowlatshahi | Jan 2014 | A1 |
20140025057 | Hoey et al. | Jan 2014 | A1 |
20140031785 | Schwagten et al. | Jan 2014 | A1 |
20140051959 | Gliner et al. | Feb 2014 | A1 |
20140058244 | Krocak | Feb 2014 | A1 |
20140058375 | Koblish | Feb 2014 | A1 |
20140081111 | Tun et al. | Mar 2014 | A1 |
20140081112 | Kim et al. | Mar 2014 | A1 |
20140081262 | Koblish et al. | Mar 2014 | A1 |
20140094794 | Orszulak | Apr 2014 | A1 |
20140142561 | Reu et al. | May 2014 | A1 |
20140171821 | Govari et al. | Jun 2014 | A1 |
20140171936 | Govari et al. | Jun 2014 | A1 |
20140180077 | Huennekens et al. | Jun 2014 | A1 |
20140187949 | Zhao et al. | Jul 2014 | A1 |
20140188440 | Donhowe et al. | Jul 2014 | A1 |
20140194867 | Fish et al. | Jul 2014 | A1 |
20140207010 | Schecter | Jul 2014 | A1 |
20140214017 | Brannan | Jul 2014 | A1 |
20140214110 | Yang et al. | Jul 2014 | A1 |
20140243813 | Paul et al. | Aug 2014 | A1 |
20140249510 | Koblish et al. | Sep 2014 | A1 |
20140249521 | McCarthy et al. | Sep 2014 | A1 |
20140257261 | Kim et al. | Sep 2014 | A1 |
20140276716 | Melsheimer | Sep 2014 | A1 |
20140276755 | Cao et al. | Sep 2014 | A1 |
20140276811 | Koblish et al. | Sep 2014 | A1 |
20140288548 | Kim et al. | Sep 2014 | A1 |
20140336638 | Deem et al. | Nov 2014 | A1 |
20140343416 | Panescu et al. | Nov 2014 | A1 |
20140378956 | Shafirstein | Dec 2014 | A1 |
20150011995 | Avitall et al. | Jan 2015 | A1 |
20150105645 | Subramaniam et al. | Apr 2015 | A1 |
20150126995 | Govari et al. | May 2015 | A1 |
20150133914 | Koblish | May 2015 | A1 |
20150133920 | Rankin et al. | May 2015 | A1 |
20150342676 | McCarthy et al. | Dec 2015 | A1 |
20160038229 | McCarthy et al. | Feb 2016 | A1 |
20160199131 | Allison et al. | Jul 2016 | A1 |
20160278841 | Panescu et al. | Sep 2016 | A1 |
20160278842 | Panescu et al. | Sep 2016 | A1 |
20160278856 | Panescu et al. | Sep 2016 | A1 |
20160317210 | McCarthy et al. | Nov 2016 | A1 |
20160324567 | Panescu et al. | Nov 2016 | A1 |
20160324568 | Panescu et al. | Nov 2016 | A1 |
Number | Date | Country |
---|---|---|
0746372 | May 2003 | EP |
1008327 | Oct 2008 | EP |
2008602 | Dec 2008 | EP |
1803407 | Nov 2010 | EP |
2294490 | Mar 2011 | EP |
1962710 | Aug 2015 | EP |
1962708 | Sep 2015 | EP |
H06-503028 | Apr 1994 | JP |
H06-510450 | Nov 1994 | JP |
T-2002-523127 | Jul 2002 | JP |
2003-52736 | Feb 2003 | JP |
T-2004-500935 | Jan 2004 | JP |
T-2006-500103 | Jan 2006 | JP |
WO 199302747 | Feb 1993 | WO |
WO 199304727 | Mar 1993 | WO |
WO 1999003535 | Jan 1999 | WO |
WO 1999044523 | Sep 1999 | WO |
WO 2000010472 | Mar 2000 | WO |
WO 2000036987 | Jun 2000 | WO |
WO 2001098764 | Dec 2001 | WO |
WO 2003028572 | Apr 2003 | WO |
WO 2003047446 | Jun 2003 | WO |
WO 2003070298 | Aug 2003 | WO |
WO 2004026098 | Apr 2004 | WO |
WO 2004073505 | Sep 2004 | WO |
WO 2004084748 | Oct 2004 | WO |
WO 2004107974 | Dec 2004 | WO |
WO 2005007000 | Jan 2005 | WO |
WO 2006074571 | Jul 2006 | WO |
WO 2007019876 | Feb 2007 | WO |
WO 2008002517 | Jan 2008 | WO |
WO 2010090701 | Aug 2010 | WO |
WO 2012120498 | Sep 2012 | WO |
WO 2013009977 | Jan 2013 | WO |
WO 2013019544 | Feb 2013 | WO |
WO 2013034629 | Mar 2013 | WO |
WO 2013119620 | Aug 2013 | WO |
WO 2013123020 | Aug 2013 | WO |
WO 2013138262 | Sep 2013 | WO |
2013188640 | Dec 2013 | WO |
WO 2014097300 | Jun 2014 | WO |
WO 2015033317 | Mar 2015 | WO |
WO 2015042173 | Mar 2015 | WO |
WO 2015104672 | Jul 2015 | WO |
WO 2015200518 | Dec 2015 | WO |
WO 2016081598 | May 2016 | WO |
WO 2016081602 | May 2016 | WO |
WO 2016081606 | May 2016 | WO |
WO 2016081611 | May 2016 | WO |
WO 2016081650 | May 2016 | WO |
20160153561 | Sep 2016 | WO |
Entry |
---|
China National Intellectual Property Administration, Notice on the Third Office Action, for corresponding Application No. 201580073126.4, dated May 26, 2020, 15 pages. |
China National Intellectual Property Administration, Notice on the Fourth Office Action and Search Report, for related Chinese Application No. 201580073126.4, dated Dec. 1, 2020, 20 pages. |
International Search Report and Written Opinion dated Feb. 3, 2016 for corresponding International Application No. PCT/US2015/061360, International filing date; Nov. 18, 2015; Consisting of 20 pages. |
Anter et al, “High-Resolution Mapping of Scar-Related Atrial Arrhythmias Using Smaller Electrodes with Closer Interelectrode Spacing,” Circ. Arrhythm. Electrophysiol. 8(3):537-45 (2015). |
Arunachalam et al., “Characterization of a digital microwave radiometry system for noninvasive thermometry using temperature controlled homogeneous test load,” Phys. Med. Biol. 53(14): 3883-3901, Jul. 21, 2008. |
Calkins, “Breaking News! When It Comes to Complications of Catheter Ablation of Atrial Fibrillation, Experience Matters,” Circulation, 2013; 128: 2099-2100 (Sep. 2013). |
Carr, “Thermography: Radiometric sensing in medicine,” New Frontiers in Medical Device Technology, Edited by Rosen et al., pp. 311-342, 1995. |
Chierchia et al., “An Initial Clinical Experience with a Novel Microwave Radiometry Sensing Technoiogy used in Irrigated RF Ablatien for Flutter” (date: Jan. 1, 2011). |
Constellation™, Full Contact Mapping Catheter, Boston Scientific Corporation Brochure, Dec. 2014. |
El-Sharkawy et al., “Absolute temperature monitoring using RF radiometry in the MRI scanner,” IEEE Trans Circuits Syst I Regul Pap. 53(11): 2396-2404, Nov. 2006. |
Ikeda et al., “Microwave Volumetric Temperature Sensor Improves Control of Radiofrequency Lesion Formation and Steam Pop,” Presentation Abstract, May 2012. |
Ikeda et al., “Novel Irrigated Radiofrequency Ablation Catheter With Microwave Volumetric Temperature Sensor Predicts Lesion Size and Incidence of Steam Pop in Canine Beating Heart,” Presentation Abstract, May 2012. |
Jacobsen et al., “Dual-mode antenna design for microwave heating and noninvasive thermometry of superficial tissue disease,” IEEE Transactions on Biomedical Engineering 47(11): 1500-1509, Nov. 2000. |
Johnson et al., “Automatic Temperature Controller for Multielement Array Hyperthermia Systems”, IEEE Transactions on Biomedical Engeineering, vol. 53, No. 6, 1006-1015, Jun. 2016. |
Koruth et al., “Occurrence of Steam Pops During Irrigated RF Ablation: Novel Insights from Microwave Radiometry,” J. Cardiovasc. Electrophysiol., vol. 24, Issue 11, pp. 1271-1277, Nov. 2013. |
Koruth et al., “Tissue Temperature Sensing During Irrigated Radiofrequency Ablation: A Novel Strategy To Predict Steam Pops,” Presentation Abstract, May 2012. |
Lantis et al, “Microwave Applications in Clinical Medicine,” Surgical Endoscopy, vol. 12, Issue 2, pp. 170-176, Feb. 1998. |
Panescu et al., Three-Dimensional Finite Element Analysis of Current Density and Temperature Distributions During Radio-Frequency Ablation, IEEE Transactions on Biomedical Engineering (1995) 42(9):879-889. |
Price et al., “Novel Ablation Catheter Technology that Improves Mapping Resolution and Monitoring of Lesion Maturation”, The Journal of Innovations in Cardiac Rhythm Management, vol. 3, 599-609, Jan. 2012. |
Rozen et al., “Prediction of radiofrequency ablation lesion formation using a novel temperature sensing technology incorporated in a force sensing catheter”, Heart Rhythm, vol. 14, No. 2, pp. 248-254, Feb. 2017. |
Schecter et al., “Palpation of Intra-cardiac Blood Flow, Pressure, Contact Force and Motor Reaction Time of Subjects Using a Novel Haptic Feedback System”, Poster Contributions, JACC vol. 65, Issue 10S, Mar. 17, 2015. |
Schecter et al., “Tactile Feedback Provides Real Time in Vivo TissuE:Catheter Contact Force Information During Cardiac Radiofrequency Ablation”—Abstract, Journal of Cardiovascular Electrophysiology, vol. 27, No. 5, p. 649, May 2016. |
Stevenson, “Irrigated RF ablation: Power titration and fluid management for optimal safety and efficacy,” Biosense Webster, Inc., 4 pages, 2005. |
Tokmakoff et al., “Thermal Diffusivity Measurements of Natural and Isotopically Enriched Diamond by Picosecond Infrared Transient Grating Experiments,” Appl. Phys., A56, pp. 87-90 (1993). |
Tungjitkusolmun et al., “Finite element analyses of uniform current density electrodes for radio-frequency cardiac ablation,” in IEEE Transactions on Biomedical Engineering, vol. 47, No. 1, pp. 32-40, Jan. 2000. |
Tungjitkusolmun et al., “Three-dimensional finite-element analyses for radio-frequency hepatic tumor ablation,” in IEEE Transactions on Biomedical Engineering, vol. 49, No. 1, pp. 3-9, Jan. 2002. |
Vandekerckhove et al., “Flutter Ablation with an Irrigated Catheter Using Microwave Radiometry Sensing Technology: first report in men” (date: Jan. 1, 2011). |
Wang et al., “Microwave Radiometric Thermometry and its Potential Applicability to Ablative Therapy,” Journal of Interventional Cardiac Electrophysiology, vol. 4, pp. 295-300, Apr. 2000. |
Wang et al., “Tissue Dielectric Measurement Using an Interstitial Dipole Antenna,” IEEE Trans Biomed. Eng., vol. 59, No. 1, 115-121, Jan. 2012. |
Yazdandoost et al., “Theoretical study of the power distributions for interstitial microwave hyperthermia,” Proceedings of the 2002 WSEAS International Conferences, Cadiz, Spain, pp. 1021-1025, Jun. 12-16, 2002. |
European Patent Office, Supplementary European Search Report for corresponding Application No. EP 18 79 0093, dated Feb. 15, 2021, 6 pages. |
Japan Office Action, dated Apr. 2, 2020 for corresponding JP Application No. 2017-527658, 13 pages. |
Number | Date | Country | |
---|---|---|---|
20190125427 A1 | May 2019 | US |
Number | Date | Country | |
---|---|---|---|
62193547 | Jul 2015 | US | |
62081710 | Nov 2014 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15179861 | Jun 2016 | US |
Child | 16231304 | US | |
Parent | PCT/US2015/061360 | Nov 2015 | US |
Child | 15179861 | US |